

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/46399 A2

(51) International Patent Classification⁷: C12N 15/10,
15/81, C07K 14/47, G01N 33/68, A61K 38/00

(21) International Application Number: PCT/US01/47817

(22) International Filing Date:
10 December 2001 (10.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/254,495 8 December 2000 (08.12.2000) US

(71) Applicant: THE BOARD OF TRUSTEES OF THE
UNIVERSITY OF ILLINOIS [US/US]; 319 Ceramics
Building, 105 South Goodwin Avenue, Urban, IL 61801
(US).

(72) Inventors: KRANZ, David, M.; 2202 O'Donnell Drive,
Champaign, IL 61821 (US). BROPHY, Susan; 705 E. Col-
orado Avenue #214, Urbana, IL 61801 (US).

(74) Agents: FERBER, Donna, M. et al.; Greenlee, Winner
and Sullivan, P.C., 5370 Manhattan Circle, Suite 201, Boul-
der, CO 80303 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/46399 A2

(54) Title: MUTATED CLASS I MAJOR HISTOCOMPATIBILITY PROTEINS AND COMPLEXES

(57) Abstract: Provided herein are combinatorial containing chimeric Major Histocompatibility Complex (MHC) Class I proteins displayed on the surfaces of recombinant yeast cells. Members of the libraries, especially where those libraries have been mutagenized either with error-prone Polymerase Chain Reaction or with site-directed oligonucleotide mutagenesis, are improved in conformation stability or in binding to a target, e.g., a peptide or other ligands as compared with the stability or binding affinity of a wild type MHC Class I chimeric protein. The improved mutant chimeric proteins can be selected by various means, including fluorescence activated cell sorting with a fluorescent ligand bound to the surfaces of the yeast cells displaying the improved mutant chimeric protein.

MUTATED CLASS I MAJOR HISTOCOMPATIBILITY PROTEINS AND COMPLEXES

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Continuation-in-Part of United States application No. 60/254,495, filed December 8, 2000.

ACKNOWLEDGMENT OF FEDERAL RESEARCH SUPPORT

This invention was made, at least in part, with funding from the National Institutes of Health (Grant No. PHS 5 RO1 AI35990). Accordingly, the United States Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

The field of the present invention is molecular biology, in particular, as it is related to combinatorial libraries of immune cell proteins displayed on the cell surface of a recombinant host cell. More specifically, the present invention relates to a library of major histocompatibility locus proteins displayed on the surfaces of recombinant yeast cells, to mutant MHC Class I and proteins selected for improved binding to particular target peptides, to mutant MHC Class I proteins selected for binding to a particular antigen, to MHC Class I proteins of improved stability and to the use of the selected high affinity and/or more stable MHC derivatives in diagnostic methods and imaging assays, among other applications including prophylactic and therapeutic treatments.

Proteins encoded by the major histocompatibility complex (called MHC proteins) are requisite components of the antigenic complexes that are involved in many diseases. These diseases include cases where the body reacts with one's own MHC proteins (in various autoimmune diseases) or infectious diseases and cancer, where the MHC are critical in binding and presenting foreign, antigenic peptides. In this invention, MHC proteins of the class I type were expressed as heterologous, surface-linked fusions on yeast cells with the goal of

generating improved MHC proteins. Libraries of mutant MHC and mutant peptide-MHC complexes could be screened for higher surface levels in order to identify variants that exhibited improved properties, including enhanced stability. For the first time, this system allows the directed evolution of MHC molecules that represent novel agents for various diagnostic and therapeutic applications. These agents could be used in cancer, infectious diseases (e.g., virus infections), and autoimmune diseases (e.g., multiple sclerosis, type I diabetes, rheumatoid arthritis).

T cell receptors (TCRs) and antibodies have evolved to recognize different classes of ligands. Antibodies function as membrane-bound and soluble proteins that bind to soluble antigens, whereas in nature, TCRs function only as membrane-bound molecules that bind to cell-associated peptide/MHC antigens. All of the energy of the antibody:antigen interaction focuses on the foreign antigen, whereas a substantial fraction of the energy of the TCR:peptide/MHC interaction seems to be directed at the self-MHC molecule [Manning et al. (1998) *Immunity* 8:413:425]. In addition, antibodies can have ligand-binding affinities that are orders of magnitude higher than those of TCRs, largely because of the processes of somatic mutation and affinity maturation. In their normal cellular context, TCRs do not undergo somatic mutation, and the processes of thymic selection seem to operate by maintaining a narrow window of affinities [Alam et al. (1996) *Nature* 381:616-620]. The association of TCRs at the cell surface with the accessory molecules CD4 or CD8 also may influence the functional affinity of TCRs [Garcia et al. (1996) *Nature* 384:577-581]. Despite these differences, the three-dimensional structures of the two proteins are remarkably similar, with the hypervariable regions forming loops on a single face of the molecule that contacts the antigen.

There is a long felt need in the art for Class I MHC proteins and Class I MHC/peptide complexes with improved stability and/or with improved T cell regulatory properties. Such improved Class I MHC proteins or complexes are useful in activating T cells that participate in the removal of target cells including neoplastic cells and cells infected with pathogenic agents including, but not limited to, viruses, protozoans, bacteria, fungi or nematodes. The

improved Class I MHC proteins and complexes of the present invention are also improved for use as research tools.

SUMMARY OF THE INVENTION

5 The present invention provides combinatorial libraries of Class I MHC proteins displayed on the surfaces of recombinant host cells, for example, yeast cells, desirably, *Saccharomyces cerevisiae*. From such a library can be isolated mutant MHC proteins that exhibit a relatively high affinity for a peptide ligand of interest. Also within the scope of the present invention are methods for isolating mutant Class I MHC proteins with improved
10 stability, especially as MHC/peptide complexes of improved stability.

 The present invention further provides Class I MHC/peptide complexes and proteins that exhibit increased stability over the wild type Class I MHC/peptide complex or MHC protein, and which MHC proteins exhibit high affinity for a peptide ligand interest. This
15 ligand can be a peptide, a protein, a carbohydrate moiety, or a lipid moiety, among others.

 Suitable labels allowing for detection of a ligand bound to an MHC protein, directly or indirectly, include but are not limited to fluorescent compounds, chemiluminescent compounds, radioisotopes, chromophores, and others. The stable, MHC protein of the present invention,
20 where it specifically binds to a tumor cell antigen with high affinity and specificity can be used in diagnostic tests to detect T cells that are specific for the Class I MHC/peptide complex. The Class I MHC/peptide complexes of the present invention can also be used to activate T cells and thus, to enhance an immune response to an antigen or target cell of interest.

25 Also provided by the invention are novel yeast display vectors and surface expression constructs in which the portion of the fusion protein that mediates attachment to the cell surface (the AGA2 sequence) is located downstream, or at the carboxy end of the protein/sequence of interest. See Fig. 2.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides a ribbon diagram corresponding to the crystal structure of a class I major histocompatibility complex with highlighted subunits. The MHC is trimeric. The MHC K^b α chain (~350 amino acids) binds to an 8-10 amino acid residue peptide in the peptide binding cleft. The β2 microglobulin (99 amino acids) associates non-covalently with the α chain.

Figure 2 illustrates the displayed MHC protein of interest displayed on the yeast cell surface via a disulfide linkage through the AGA2 portion of the fusion protein comprising the MHC component.

Figure 3 illustrates diagrammatically the pCT302 yeast surface display vector which contains a sequence encoding AGA2/HA-Class I MHC - *c-myc* fusion protein. This fusion protein coding sequence is expressed in yeast under the regulatory control of the GAL1-10 promoter. A similar vector, pYD1, is commercially available from Invitrogen.

Figure 4 provides diagrams of various single-chain Class I MHC constructs cloned into the pCT302 Yeast Display Vector.

Figure 5 provides the results of flow cytometric analyses of various K^b constructions. Yeast cells displaying K^b/β2m, SIYR K^b/β2m, dEV8-K^b/β2m, and OVA K^b/β2m were stained with anti-*c-myc* Mab 9E10 and biotinylated anti-K^b antibody (B.8.24.3) followed by FITC labeled F(ab')₂ goat anti-mouse IgG or SA-PE (shaded peaks). For a background control, yeast were treated with only the secondary stain (unshaded peak). Labeled yeast were analyzed on Coulter Epics XL flow cytometer. All four constructions displayed the properly folded K^b molecule on the surface.

Figure 6A-6D illustrate histograms from CD69 up-regulation assays. Induction of T cell activation marker CD69 on naïve splenocytes (10⁶) in the presence of K^b/β2m, anti-TCR scFv, and SIYR/K^b/β2m yeast cells. Induced yeast cells (10⁶) were incubated at 37°C and 5% CO₂ with splenocytes from 2C TCR/RAG-1^{-/-} mice. After 20 hours in culture, cells were

harvested, washed in PBS/0.5% BSA and stained with biotinylated clonotypic antibody, 1B2 [Kranz et al. (1984) *Proc. Natl. Acad. Sci. USA* 81: 7922-7926] for 45 minutes. These yeast were washed and stained with a mixture of the early activation marker FITC anti-CD69 antibody and SA:PE. The yeast/T cell mixture was analyzed for bound FITC-labeled anti-CD69 antibody by flow cytometry, gating on 1B2 positive T cells. The mean fluorescence units for FITC anti-CD69 antibody in the absence of yeast, presence of K^b/b2m yeast, anti-TCR scFv yeast, and SIYR/K^b/β2m yeast are indicated and illustrated in the histograms. Yeast cells that expressed K^b with the agonist peptide (called "SIYR"; SIYRYYYGL SEQ ID NO:1), but not yeast cells with K^b and no peptide, were capable up-regulating the CD69 molecule on the 2C T cells. This up-regulation was even greater than observed with the positive control anti-TCR antibody KJ16 [Cho et al. (1998) *J. Immunol. Methods* 220(1-2): 179-188].

Figure 7 shows the results of direct activation of T cells by yeast that express Class I Peptide/MHC, as measured by flow cytometry. Up-regulation on 2C TCR/RAG^{-/-} splenocytes incubated with varying ratios of yeast (3 to 100 x 10⁵ yeast and 10⁶ T cells) were analyzed by flow cytometry. The mean fluorescence units of FITC anti-CD69 antibody was detected on 1B2 gated T cells following 20 hours of incubation (37°C, 5% CO₂) of 2C TCR/RAG^{-/-} splenocytes with yeast that expressed: SIYR/K^b/β2m, anti-TCR scFv (positive control), and K^b/β2m (negative control).

Figure 8 shows direct activation of T cells by pMHC on yeast, thus providing evidence for pMHC specificity excess peptide and anti-K^b antibody inhibit CD69 up-regulation. In order to confirm the specificity of T cell activation, K^b/β2m (negative control), SIYR/K^b/β2m bearing yeast cells, and 2C TCR/RAG^{-/-} splenocytes were incubated with excess OVA (SIINFEKL, SEQ ID NO:2) peptide or anti-K^b antibody (50 μg/ml B.8.24.3) at 37°C, 5% CO₂. Excess OVA peptide binds to K^b and should compete for binding to the K^b molecule, but it is not recognized by 2C T cells. Anti-K^b antibody recognizes the α1/α2 helices and should prevent binding by the T cell receptor from 2C T cells. After 1 hour, 2C TCR/RAG^{-/-} splenocytes were mixed with the yeast and incubated for 20 hrs. Detection of CD69 on 2C T cells following incubation with yeast in the absence or presence of inhibitors was detected with FITC anti-CD69 antibody and reported as the mean fluorescence units. Both excess OVA

peptide and the anti-K^b antibody inhibited the up-regulation of CD69, confirming that the recognition of the yeast-bound SIYR/K^b was specific.

Figure 9 diagrammatically illustrates cloning and transformation via homologous recombination. Linear mutagenized MHC protein coding sequence and linearized pCT302 vector are co-electroporated into yeast. This strategy is used in the preparation of the yeast display library for the MHC Class I protein.

Figure 10 illustrates the strategy for mutagenizing a yeast display library and screening that library by taking advantage of the binding properties of mutant vs wild type displayed proteins. Fluorescently labeled ligands or antibodies which bind the displayed protein are employed in flow cytometry assays.

Figure 11 provides examples of sorting libraries generated by random mutagenesis. A SIYR/K^b/β2m error prone library (SEP) and a dEV8/K^b/β2m error prone library (dEP) were each sorted 3 times. The SEP and dEP yeast (10⁷), after having been induced for 2 days, were washed with PBS/0.5% BSA, stained with biotinylated anti-K^b (B.8.24.3) for 60 min, washed again, and stained with SA:PE for 30 min. The first sort isolated the top 1.0% of the population using a 1:25 dilution of anti-K^b. The second and third sorts were stained with a 1:250 and 1:500 dilution of anti-K^b for SEP and 1:250 dilution for both the second and third sort of dEP. The second and third sorts isolated the top 0.25% and 0.1% of the population, respectively. Representative histograms from the second and third sort of the SEP library illustrate the mean fluorescence shift of the total population or enhancement of the more fluorescent yeast cells from sort 2 to sort 3. This indicated that there were likely to be K^b mutants that exhibited increased stability and hence, increased surface levels [Shusta, (1999) *J. Mol. Biol.* 292: 949-956].

Figure 12 shows the K^b surface levels of mutant clones isolated by sorting from dEV8/K^b error prone PCR library. Following sorting, ten randomly selected clones from the dEV8/K^b/β2m library were analyzed on the flow cytometer for binding to the biotinylated anti-

K^b antibody (B.8.24.3). Binding was detected with SA:PE, and mean fluorescence for each clone was determined.

Figure 13 shows sequences of mutant clones isolated by sorting from dEV8/K^b error prone PCR library. The mutations in three clones selected from the dEV8/K^b/β2m error prone library (sort 3) and the crystal structure with two of the mutations (W167R, Y63N) are shown.

Figure 14 illustrates construction of a directed, mutagenic peptide library in dEV8/K^b library construction. Mutagenic PCR of positions 1-3 of the peptide dEV8 was performed using the degenerate upstream primer (5' ATA TTT TCT GTT ATT GCT TCA GTT TTA GCA GCT AGC TTG GAT AAA AGA NNS NNS NNS AAA TTC 3', SEQ ID NO:3) and a downstream vector-specific primer. Using homologous recombination, the mutagenic dEV8/K^b/β2m PCR product and *Nhe* I-*Nde* I digested dEV8/K^b/β2m pCT302 were electroporated into electrocompetent yeast (BY5465, strain EBY100). A dilution of the transformed library was plated on SD-CAA plates and incubated for 3 days at 30°C to obtain the library size (7 x 10³).

Figure 15 shows the properly folded α3 domain, but the α1/α2 domains of L^d are not displayed on yeast. L^d/β2m yeast cells were pulsed for two hours with the L^d-binding peptide QL9 (QLSPFPFDL, SEQ ID NO:4), washed with PBS/0.5%BSA, and stained with anti-L^d antibodies, 28.14.8 (α3 specific) or 30-5-7 (α1/α2 specific). After 45 min, cells were washed and stained with FITC-labeled F(ab')₂ goat anti-mouse IgG, and binding was detected using flow cytometry. The histograms generated from the L^d/β2m displaying yeast represent the binding of the α3 specific antibody (28.14.8). The 30-5-7 antibody, α1/α2 specific, did not show the same binding (histograms not included), suggesting that at least one of these two domains was not folded properly and thus might be stabilized by a process of directed evolution and yeast display.

Figure 16 illustrates the result of sorting a yeast display mutant library of "unstable" Class I MHC L^d. Yeast cells displaying L^d/β2m were induced at 20 C for 2 days in the presence of an L^d/β2m specific peptide, QLSPFPFDL (QL9, SEQ ID NO:4). L^d/β2m yeast

were stained with supernatants from *D. melanogaster* cells expressing the high-affinity T cell receptor (m6), biotinylated anti-T cell receptor antibody (F23.1) and a streptavidin-phycoerythrin (SA:PE) conjugate (shaded peak). The L^d/β2m yeast cells were also stained with an α2 domain specific antibody (30-5-7) and an α3 domain specific antibody (28.14.8) followed by a FITC labeled F(ab')₂ goat anti-mouse IgG (shaded peak). For a background control, yeast cells were treated with only the secondary stains (unshaded peaks). Labeled yeast cells were detected using a Coulter EPICS XL flow cytometer. The L^d/β2m α3 domain was folded properly on the surface, but not the α2 domain or the TCR binding domain.

Figure 17 demonstrates that the L^d mutant 30.8 exhibits a properly folded TCR binding domain and properly folded α2/α3 domains. An L^d/β2m error prone library was created using homologous recombination and electroporation into electrocompetent *S. cerevisiae* EBY100 cells. The L^d/β2m error prone yeast library was sorted with L^d/β2m α3 specific antibody, 28.14.8, and an L^d/β2m α2 specific antibody, 30-5-7. Sorted yeast cells were screened by flow cytometry for binding to 30-5-7 antibody and high affinity T cell receptor supernatant (m6), as described in Fig. 16 above. Unlike yeast cells that express the wild type L^d/β2m, the L^d/β2m mutant, yeast cells expressing 30.8 were detected by the α2 specific antibody (30-5-7) and by the high affinity T cell receptor (m6) when the correct peptide (QL9) was added exogenously. Mutant 30.8 was also detected by the α3 specific antibody, 28.14.8.

Figure 18 summarizes the results for a yeast display library of peptides that bind to MHC class I K^b. Known K^b peptides (SIYRYGL, SEQ ID NO:1; EYKIFYSV, SEQ ID NO:5; SIINFEKL, SEQ ID NO:2) have anchor residues at peptide positions 5 and 8. P5 requires an aromatic amino acid whereas P8 requires a hydrophobic amino acid. Yeast displaying a K^b peptide binding motif, but with the AGA2 fused at the amino terminus, were isolated after incubation of yeast cells with the dEV8 (EYKIFYSV)/K^b tetramer.

Figure 19 shows that yeast cells displaying the K^b peptide motif were detected by flow cytometry using a fluorescent-labeled K^b tetramer. Yeast cells with the C-terminal sequence shown in the top panel were stained with dEV8 (EYKIFYSV)/K^b tetramers for 12 hours. The dEV8 peptide dissociates from the K^b pocket, and the AGA2-fused peptide on the yeast surface

binds to the free K^b. Binding of the peptide motif to the K^b tetramer was detected by flow cytometry (shaded peak). For a background control, yeast cells were treated with streptavidin-phycoerythrin (SA:PE) conjugate alone. Mutagenic substitution of the proline residue at position P4 with an alanine residue reduced binding significantly (bottom panel), indicating that the proline is important in K^b-binding.

Figure 20 shows that novel class I MHC binding peptides are isolated by yeast display technology. Using the lead peptides identified by yeast display experiments (Fig. 19), one can now identify improved peptides by production of libraries that contain mutations in non-anchor residues (e.g. P6, P7, and P9).

DETAILED DESCRIPTION OF THE INVENTION

The role of proteins encoded by the major histocompatibility complex (called MHC proteins) has now been known for almost twenty years. MHC proteins are expressed by every individual and function as "antigen-presenting" molecules. That is, each MHC protein can bind to a variety of different small peptides (8 to 20 amino acids in length) that are derived from proteins present inside a cell. MHC proteins present both self-peptides (i.e., derived from an individual's own endogenous proteins) and foreign peptides (i.e., derived from a foreign agent such as a virus). Once a peptide is bound to the MHC protein, the entire peptide-MHC complex is expressed on the surface of the cell. If the peptide is foreign, a T lymphocyte (T cell) can potentially recognize the complex, and the resultant interaction of the T cell receptor (TCR) and the pMHC can result in T cell activation. T cell activation can lead to recruitment of other immune cells and a corresponding inflammatory reaction. Such inflammatory reactions are beneficial if the pMHC target antigen is, in fact, derived from an infectious agent or from a transformed cell (i.e., cancer). However, such inflammatory reactions can be very detrimental if the pMHC target antigen is derived from self tissue, as the reactions can lead to severe autoimmune disease, where an individual's immune system attacks normal tissue. Such is the case when a patient's lymphocytes attack the islet cells of the pancreas (type I diabetes), the nervous system (multiple sclerosis), or joint-derived components (rheumatoid arthritis).

The central role of pMHC complexes in these phenomena has been established by thousands of published studies that include genetic linkages of diseases to the human MHC locus (HLA). It has now also been established that it is possible to use appropriately characterized peptide-MHC molecules as either agonists of an immune response (e.g., in cancer and infectious diseases) or as antagonists of responses (e.g., in autoimmune responses). While several approaches have been taken to produce such pMHC complexes in soluble forms for these purposes and for biochemical/structural studies, it has not been possible to use current methods of in vitro directed evolution to improve the stability or antigenicity of the pMHC complex. This is because the pMHC complex is normally a membrane-associated complex composed of multiple different subunits (heavy chain, beta-2-microglobulin, and peptide in the case of a class I MHC and α -chain, β -chain, and peptide in the case of class II MHC) and such proteins are typically not amenable to the current methods of directed evolution (primarily phage display). The present invention shows that a display system for directed evolution can be used to express properly folded Class I MHC proteins on the surface of yeast. The displayed peptide-MHC complexes can be used to directly activate T cells, in order to identify/screen for pMHC antigens. In addition, mutated libraries of the pMHC proteins could be created and used for selection by flow sorting of stabilized pMHC variants. The stabilized variants can be identified because they were expressed at higher levels on the yeast surface and can therefore be easily identified by using a fluorescent-labeled probe for the pMHC construct, combined with high-throughput flow cytometric sorting or such cells.

The Class I MHC proteins (see Fig. 1 for ribbon diagram) are composed of an α chain of 350 amino acids and a β 2m chain of 99 amino acids; the two chains are noncovalently associated with one another. Peptides that are about 8-10 residues bind the Class I MHC molecules. About 10^5 to 10^6 peptide-Class I MHC complexes are displayed on the surfaces of nucleated cells. Class I MHC complexes are involved in the recognition of virus infected cells, pathogen-infected cells, and tumor antigens by cytotoxic T lymphocytes.

To date, no Class I MHC protein has been crystallized without a peptide bound in the peptide binding cleft. Some Class I MHC proteins are difficult or impossible to produce in soluble form because of their instabilities. For example, the mouse Class I MHC K^b is

relatively stable, and it has been used in many studies. By contrast, the mouse Class I MHC L^d is less stable, and it has been more difficult to produce. The stability of a particular peptide-Class I MHC complex is directly related to its ability to stimulate efficient T cell responses, for example, in vaccine applications. A system for the in vitro evolution of more stable peptide-MHC complexes allows for novel agents and vaccines to be used in stimulating protective immune responses against diseases and neoplastic conditions.

The present invention allows the creation and isolation of stabilized variants of peptide-MHC complexes. Toward this end, we have displayed single-chain peptide/Class I MHC (α chain/ β 2m) complexes on the surface of yeast cells. Yeast cells expressing a specific peptide/MHC complex (SIYR/K^b) on the cell surface were capable of directly activating T cells, thus providing a method for screening powerful T cell agonists. Mutant libraries of a less stable peptide/MHC complex (dEV8/K^b) were made and expressed, and mutant MHC polypeptides of increased stability were isolated. Similarly, the less stable MHC L^d was expressed as a mutant library displayed on the surface of recombinant yeast cells, and more stable L^d variants were isolated using flow cytometry screening methodology. WO 99/36569, incorporated by reference herein, provides abundant discussion of this display technology.

Fig. 2 illustrates the MHC protein of interest displayed on the yeast cell surface via a disulfide linkage through the AGA2 portion of the fusion protein comprising the MHC component. AGA2 is a mating adhesion receptor which is naturally bound to the cell surface in disulfide linkage to the AGA1 protein. The HA and the *c-myc* portions of the displayed fusion protein serve as epitope tags and can be used in normalizing the fluorescent peptide binding data. Each recombinant yeast cell displays about 50,000 copies of the surface-bound fusion protein (if stable) on its surface. A fluorescent antibody or peptide ligand is added, and the cells are sorted using flow cytometry. Those MHC fusion proteins of increased stability exhibit stronger binding of the fluorescent ligand, and these cells are selected during the cell sorting procedure.

Fig. 3 illustrates diagrammatically the pCT302 yeast surface display vector which contains a sequence encoding AGA2/HA-Class I MHC - *c-myc* fusion protein. This fusion

protein coding sequence is expressed in yeast under the regulatory control of the GAL1-10 promoter. A similar vector, pYD1, is commercially available from Invitrogen (Carlsbad, CA).

Fig. 4 shows various constructs for the expression of fusion proteins containing portions representing the peptide binding portions of various Class I MHC proteins. Surprisingly, the AGA2 portion was functional either at the N-terminus or the C-terminus of the fusion protein, and it mediated binding to the yeast cell wall surface when associated with any of the protein portions tested and in both the amino- or carboxyl terminal positions. In Fig. 4 SS refers to a signal peptide sequence necessary for proper intracellular transport of the fusion protein. The signal peptide is cleaved prior to display on the cell surface. The MHC polypeptide coding portion includes a sequence encoding a 15 amino acid spacer between the COOH terminus of the α chain and the NH₂ end of the β 2m portion. HA refers to the peptide tag derived in sequence from hemagglutinin, which tag is located at the amino terminus of the α chain. C-myc refers to the peptide tag at the COOH terminus of the β 2m portion. The three peptides linked at the amino terminus of K^b represent a strong agonist ("SIYR" peptide, SEQ ID NO:1), a weak agonist (dEV8) and a null peptide (OVA) for the T cell clone called 2C. The AGA2 coding sequence was cloned at the COOH termini of these constructs in order to allow free NH₂ termini of the peptides, which is generally thought to be important for proper binding to Class I MHC polypeptides. All fusion protein coding sequences were assembled using standard polymerase chain reaction (PCR) strategies.

The correct foldings of various fusion display proteins were confirmed by fluorescence activated cell sorting after binding of the recombinant yeast cells to fluorescently labeled antibody specific for c-myc or K^b. See Fig. 5.

To demonstrate the direct activation of T cells by recombinant yeast cells expressing a peptide/MHC complex, naive splenic T cells from a TCR transgenic mouse (2C TCR tg) were incubated with yeast cells expressing SIYR/K^b, K^b (negative control) or anti-TCR scFv (positive control). After about 20 hours in culture, the T cells were analyzed by flow cytometry for the up-regulation of the activation marker CD69. See Figs. 6A-6D for a graphical display of the results.

Fig. 7 shows the dependence of T cell activation on T cells and on the presence of a peptide/MHC complex. Fig. 8 demonstrates the pMHC specificity: excess free peptide and anti-K^b antibody inhibit CD69 up-regulation in T cells.

5 We have demonstrated direct activation of T cells by yeast cells that express peptide/MHC. Splenocytes (10⁶) from 2C TCR/RAG-1^{-/-} mice were combined with approximately 3-100 x 10⁵ of KF washed yeast cells displaying K^b/β2m, SIYR/K^b/β2m, or anti-TCR scFv (positive control) at 37 C; 5% CO₂ in a 24 well plate. After 20 hours in culture, cells were harvested, washed in PBS/0.5%BSA and stained with biotinylated
10 clonotypic antibody, 1B2 [Kranz et al. (1984) supra] for 45 minutes. These yeast/T cell mixtures were washed and stained with a mixture of the early activation marker FITC-labeled anti-CD69 antibody and SA:PE. The yeast/T cell mixture was analyzed for the CD69 marker (present only on activated T cells) by flow cytometry and gating on 1B2 positive T cells.

15 The yeast display system was exploited to produce a random mutagenized library from which stabilized mutant Class I MHC K^b sequences were isolated. Constructs encoding the fusion proteins containing SIYR/K^b and dEV8/K^b portions were mutagenized randomly using error prone PCR (0.16 Mn:Mg molar ratio). The homologous recombination scheme illustrated in Fig. 9 was employed to create the libraries. From the SIYR/K^b experiment, 3.6
20 million transformants were recovered. From the dEV8/K^b experiment, 2.7 million transformants were recovered. 5 plasmid inserts from each mutated library were sequenced (about 3200 bp of sequence per library) to determine the mutation frequency. In the SIYR/K^b experiment the mutation frequency was 0.37% (2 wild type sequences, 3, 4, and 5 mutant sequences). In the dEV8/K^b experiment, there was a 0.06% mutation frequency (4 wild type,
25 1 mutant sequence).

Fig. 10 diagrammatically presents the generic screening strategy for screening the mutated yeast display libraries. Fig. 11 illustrates the results for second and third sorts with anti-K^b monoclonal antibody B.8.24.3. In the second sort the top 0.25% of the cells
30 (according to fluorescence intensity, mfu, mean fluorescence units) were selected, and in the

third sort, the top 0.1% of the cells were selected. The profiles were similar for the dEV8/K^b experiment.

Fig. 12 illustrates different K^b binding as reflected in different levels of fluorescent peptide bound after sorting of the dEV8/K^b mutant library produced using error prone PCR. Fig. 13 presents selected sequences of mutant clones isolated by sorting of the dEV8/K^b mutant library, and the positions of the mutations are shown on the ribbon diagram of the Class I MHC protein. The following provides further details on the construction of a dEV8/K^b mutant library. From the ribbon diagram it is deduced that the sequence EQYKFYSV (SEQ ID NO:5) is important. The E (P1, the first amino acid of the peptide sequence) is buried in the first pocket. Q, P2, is directed down into the pocket. Y, P3, is a bulky, secondary anchor residue. K, P3, is a primary TCR contact, and it is directed out of the pocket. The F residue (P4) is an aromatic residue directed into the pocket; it serves as a primary MHC anchor. The Y residue at P6 is a large aromatic residue which also functions in TCR contact. The S residue (P7) is a small residue; the small size is dictated by the space available. The last V residue (P8) serves as a primary anchor residue, and it is directed into the pocket. To select mutations that stabilize dEV8 binding to K^b, mutations are introduced in the library at positions that point into K^b. A degenerate library is produced at P1-P3 (i.e., NNNKFYSV, SEQ ID NO:6). That library is constructed by error prone PCR and the mutant library is introduced into the wild type dEV8/K^b plasmid by homologous transformation as shown in Fig. 9. Isolated recombinants are then sequenced. Of four sequenced, each contained different nucleotides encoding P1-P3. See Fig. 14 and its description herein above.

The motivations for using directed evolution to isolate stabilized variants of L^d include the lower stability of the wild type L^d protein based on biochemical studies, the suboptimal loading of peptides in the endoplasmic reticulum, the slower intracellular transport of L^d (4 hr v 1 hr), the lower cell surface expression (2-4 fold lower) and fewer α/β 2m contacts. See Table 1.

Fig. 15 provides data demonstrating that the properly folded α 3 domain but not the α 1/ α 2 domains of L^d are displayed on the surface of recombinant yeast cells. We have also

demonstrated that anti-L^d α 1/2 domain (monoclonal antibody 30.5.7) did not bind to the same L^d/β2m displayed on yeast cell surfaces.

In summary, the Class I MHC K^b was cloned as an AGA2 fusion in single chain format (AGA2-HA-K^b-β2m-c-myc). The full protein was detected on the yeast cell surface using an antibody that recognizes the properly folded α 1/ α 2 domains of K^b. The coding sequences of this protein were also cloned with AGA2 at the carboxy terminus, with K^b binding peptides (SIYR, dEV8 and OVA) linked at the amino termini (peptide-HA-K^b-β2m-c-myc-AGA2). Yeast that expressed the T cell specific peptide K^b on the cell surface were capable of directly activating T cells, thereby providing a system for screening T cell agonists.

To create stabilized K^b mutant fusion protein, two different mutational libraries were produced by error prone PCR to yield random mutations after subsequent homologous recombination of mutagenized coding sequence and linearized vector after co-electroporation. Mutants that displayed higher yeast surface levels, and thus presumptive enhanced stability, were identified by flow cytometry sorting.

The unstable class MHC protein L^d was also cloned as an AGA2 fusion in single chain format (AGA2-HA- L^d-β2m-c-myc). L^d was detected on the yeast cell surface with an α 3-specific antibody, but properly folded α 1/ α 2 domains were not detected with anti- L^d antibody, suggesting that stabilized variants of L^d can be engineered by directed evolution and flow sorting for improved yeast surface expression.

The present inventors have now succeeded in isolating stabilized mutants of the class I molecule L^d. The L^d molecule has been shown to be relatively unstable. When expressed in the yeast display system, only the α 3 domain appears to be folded properly on the surface (Fig. 16). The displayed protein is not recognized by a conformation-specific α 2 antibody (30-5-7) nor is the QL9/L^d complex recognized by the high-affinity T cell receptor called m6 (Fig.16). To isolate stabilized L^d, a library of random mutants was expressed in yeast, and the library was selected with anti-L^d antibody 30-5-7; see Fig.17 and its description. Various mutants were isolated. One mutant (30.8) is shown in Fig. 17. Mutant 30.8 bound to both the

$\alpha 2$ -specific antibody and the QL9/L^d (30.8) complex bound to the high affinity TCR m6, reflecting increased stability over its wild type parent protein.

Another application of the yeast display to technology is to identify peptides that bind
5 directly to MHC class I proteins. Serendipitously, we isolated a peptide that bound to the K^b
molecule even though the peptide was fused to the C-terminus of the AGA2 protein. This
finding was completely unexpected. Previously, only peptides of 8 to 10 amino acids had been
shown to bind to class I MHC products. This restriction in length was thought to be due to the
need for both the N- and C-termini to bind within pockets of the class I molecule, thereby
10 contributing binding energy to the interaction. AGA2-fusion peptides were isolated by
screening with a dEV8/K^b tetramer. A carboxy terminal peptide sequence HYSPFRQLA (SEQ
ID NO:37) that had K^b-binding consensus anchor residues at positions P5 and P8 was isolated
(Fig. 18). Yeast displaying the AGA2-fusion with the sequence HYSPFRQLA (SEQ ID
NO:37) at the C-terminus bound to dEV8/K^b tetramers (Fig. 19). This binding was a
15 consequence of the relative instability of dEV8 binding to K^b. This instability apparently
allows the peptide dEV8 to dissociate, and the surface-bound AGA2-fusion peptide binds to
the free K^b. Without wishing to be bound by any particular theory, we believe that the proline
at position P4 allows the peptide to exit the K^b-site at the residue amino terminal to the P5
anchor. This is supported by the finding that an alanine substitution mutation at this position
20 has significantly reduced binding (Fig. 19). These findings show that it is possible to create
a library of fused peptides (to AGA2) and that this library can be screened for K^b-binding (Fig.
20). Thus, the yeast display system can be used to identify novel class I-binding peptides.

In order to provide a clear and consistent understanding of the specification and claims,
25 including the scope to be given to such terms, the following definitions are provided.

A coding sequence is the part of a gene or cDNA which codes for the amino acid
sequence of a protein, or for a functional RNA such as a tRNA or rRNA.

30 Complement or complementary sequence means a sequence of nucleotides which forms
a hydrogen-bonded duplex with another sequence of nucleotides according to Watson-Crick

base-pairing rules. For example, the complementary base sequence for 5'-AAGGCT-3' is 3'-TTCCGA-5'.

Downstream means on the 3' side of any site in DNA or RNA.

5

Expression refers to the transcription of a gene into structural RNA (rRNA, tRNA) or messenger RNA (mRNA) and subsequent translation of a mRNA into a protein.

10 An amino acid sequence that is functionally equivalent to a specifically exemplified MHC protein sequence is an amino acid sequence that has been modified by single or multiple amino acid substitutions, by addition and/or deletion of amino acids, or where one or more amino acids have been chemically modified, but which nevertheless retains the binding specificity and high affinity binding activity of a cell-bound or a soluble MHC protein of the present invention. Functionally equivalent nucleotide sequences are those that encode
15 polypeptides having substantially the same biological activity as a specifically exemplified cell-bound or soluble MHC protein. In the context of the present invention, a soluble MHC protein is lacks the portions of a native cell-bound MHC and is stable in solution (i.e., it does not generally aggregate in solution when handled as described herein and under standard conditions for protein solutions).

20

Two nucleic acid sequences are heterologous to one another if the sequences are derived from separate organisms, whether or not such organisms are of different species, as long as the sequences do not naturally occur together in the same arrangement in the same organism.

25

Homology refers to the extent of identity between two nucleotide or amino acid sequences.

30

Isolated means altered by the hand of man from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a

living animal is not isolated, but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is isolated, as the term is employed herein.

5 A linker region is an amino acid sequence that operably links two functional or structural domains of a protein.

A nucleic acid construct is a nucleic acid molecule which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature.

10

Nucleic acid molecule means a single- or double-stranded linear polynucleotide containing either deoxyribonucleotides or ribonucleotides that are linked by 3'-5'-phosphodiester bonds.

15

Two DNA sequences are operably linked if the nature of the linkage does not interfere with the ability of the sequences to effect their normal functions relative to each other. For instance, a promoter region would be operably linked to a coding sequence if the promoter were capable of effecting transcription of that coding sequence.

20

A polypeptide is a linear polymer of amino acids that are linked by peptide bonds.

25

Promoter means a cis-acting DNA sequence, generally 80-120 base pairs long and located upstream of the initiation site of a gene, to which RNA polymerase binds and initiates correct transcription. There can be associated additional transcription regulatory sequences which provide on/off regulation of transcription and/or which enhance (increase) expression of the downstream coding sequence.

30

A recombinant nucleic acid molecule, for instance a recombinant DNA molecule, is a novel nucleic acid sequence formed in vitro through the ligation of two or more nonhomologous DNA molecules (for example a recombinant plasmid containing one or more inserts of foreign DNA cloned into at least one cloning site), through PCR technology or by

directed homologous recombination, e.g. by co-transformation of two or more DNA molecules having at least regions of limited sequence identity to allow for homologous recombination with the transformed cell..

5 Transformation means the directed modification of the genome of a cell by the external application of purified recombinant DNA from another cell of different genotype, leading to its uptake and integration into the subject cell's genome. In bacteria, the recombinant DNA is not typically integrated into the bacterial chromosome, but instead replicates autonomously as a plasmid.

10 Upstream means on the 5' side of any site in DNA or RNA:

A vector is a nucleic acid molecule that is able to replicate autonomously in a host cell and can accept foreign DNA. A vector carries at least one origin of replication functional in
15 at least one type of cell, one or more unique recognition sites for restriction endonucleases which can be used for the insertion of foreign DNA, and usually selectable markers such as genes coding for antibiotic resistance, and often recognition sequences (e.g. promoter) for the expression of the inserted DNA. Common vectors include plasmid vectors and phage vectors. There can be more than one origin of replication to allow for replication and maintenance in
20 more than one type of cell (e.g., separate origins of replication functional in yeast and *Escherichia coli*, respectively).

A virus infected cell is a cell in which a virus is replicating. Typically, a virus infected cell displays at least one antigen on its surface which is characteristic of the virus infection
25 process. Such an antigen can be the target of recognition by the immune system and subsequent killing of the cell.

A pathogen infected cell is a human or animal cell in which an intracellular parasite (bacterial, fungal or protozoan) is surviving or reproducing. Typically a pathogen infected cell
30 displays at least one antigen on its surface which is characteristic of the infection, and this antigen can be the target of immune recognition and targeting for killing of the infected cell.

The role of proteins encoded by the major histocompatibility complex (MHC proteins) have been known for nearly twenty years. MHC proteins are expressed by every individual, and they function as antigen-presenting molecules. Each MHC protein can bind to a variety of different small peptides (8 to 20 amino acids).

5

Recently it was demonstrated that a scTCR ($V\beta$ -linker- $V\alpha$) could be displayed on the surface of yeast [Kieke et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:5651-5656], in the yeast display system that has proven successful in antibody engineering [Boder and Wittrup (1997) *Nat. Biotech.* 15: 553-557.; Kieke et al. (1999) *supra*]. In addition, it was shown that mutations that increased the surface levels of the TCR also increased the stability of the TCR in solution [Shusta et al. (1999) *J. Mol. Biol.* 292:949-956]. Thus, yeast surface display can now be used to isolate proteins that exhibit greater stability.

10

It will be appreciated by those of skill in the art that, due to the degeneracy of the genetic code, numerous functionally equivalent nucleotide sequences encode the same amino acid sequence of an improved Class I MHC protein or class I MHC/peptide complex.

15

Additionally, those of skill in the art, through standard mutagenesis techniques, in conjunction with the antigen-finding activity assays described herein, can obtain altered MHC class I protein sequences and test them for the expression of polypeptides having particular binding activity. Useful mutagenesis techniques known in the art include, without limitation, oligonucleotide-directed mutagenesis, region-specific mutagenesis, linker-scanning mutagenesis, and site-directed mutagenesis by PCR [see e.g. Sambrook et al. (1989) *vide infra*, and Ausubel et al. (1999) *vide infra*].

20

25

In obtaining variant MHC coding sequences, those of ordinary skill in the art will recognize that MHC-derived proteins can be modified by certain amino acid substitutions, additions, deletions, and post-translational modifications, without loss or reduction of biological activity. In particular, it is well-known that conservative amino acid substitutions, that is, substitution of one amino acid for another amino acid of similar size, charge, polarity and conformation, are unlikely to significantly alter protein function. The 20 standard amino

30

acids that are the constituents of proteins can be broadly categorized into four groups of conservative amino acids as follows: the nonpolar (hydrophobic) group includes alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine; the polar (uncharged, neutral) group includes asparagine, cysteine, glutamine, glycine, serine, threonine and tyrosine; the positively charged (basic) group contains arginine, histidine and lysine; and the negatively charged (acidic) group contains aspartic acid and glutamic acid. Substitution in a protein of one amino acid for another within the same group is unlikely to have an adverse effect on the biological activity of the protein.

Homology between nucleotide sequences can be determined by DNA hybridization analysis, wherein the stability of the double-stranded DNA hybrid is dependent on the extent of base pairing that occurs. Conditions of high temperature and/or low salt content reduce the stability of the hybrid, and can be varied to prevent annealing of sequences having less than a selected degree of homology. For instance, for sequences with about 55% G - C content, hybridization and wash conditions of 40 - 50 C, 6 X SSC (sodium chloride/sodium citrate buffer) and 0.1% SDS (sodium dodecyl sulfate) indicate about 60 - 70% homology, hybridization and wash conditions of 50 - 65 EC, 1 X SSC and 0.1% SDS indicate about 82 - 97% homology, and hybridization and wash conditions of 52 C, 0.1 X SSC and 0.1% SDS indicate about 99 -100% homology. A wide range of computer programs for comparing nucleotide and amino acid sequences (and measuring the degree of homology) are also available, and a list providing sources of both commercially available and free software is found in Ausubel *et al.* (1999). Readily available sequence comparison and multiple sequence alignment algorithms are, respectively, the Basic Local Alignment Search Tool (BLAST) (Altschul *et al.*, 1997) and ClustalW programs. BLAST is available on the Internet at <http://www.ncbi.nlm.nih.gov> and a version of ClustalW is available at <http://www2.ebi.ac.uk>.

Industrial strains of microorganisms (e.g., *Aspergillus niger*, *Aspergillus ficuum*, *Aspergillus awamori*, *Aspergillus oryzae*, *Trichoderma reesei*, *Mucor miehei*, *Kluyveromyces lactis*, *Pichia pastoris*, *Saccharomyces cerevisiae*, *Escherichia coli*, *Bacillus subtilis* or *Bacillus licheniformis*) or plant species (e.g., canola, soybean, corn, potato, barley, rye, wheat) may be used as host cells for the recombinant production of the mutant MHC proteins of the present

invention. As the first step in the heterologous expression of a high affinity MHC protein or soluble protein, an expression construct is assembled to include the MHC or soluble MHC coding sequence and control sequences such as promoters, enhancers and terminators. Other sequences such as signal sequences and selectable markers may also be included. To achieve
5 extracellular expression of a soluble MHC polypeptide, the expression construct may include a secretory signal sequence. The signal sequence is not included on the expression construct if cytoplasmic expression is desired. The promoter and signal sequence are functional in the host cell and provide for expression and secretion of the MHC or soluble MHC protein. Transcriptional terminators are included to ensure efficient transcription. Ancillary sequences
10 enhancing expression or protein purification may also be included in the expression construct.

Various promoters (transcriptional initiation regulatory region) may be used according to the invention. The selection of the appropriate promoter is dependent upon the proposed expression host. Promoters from heterologous sources may be used as long as they are
15 functional in the chosen host.

Promoter selection is also dependent upon the desired efficiency and level of peptide or protein production. Inducible promoters such *tac* are often employed in order to dramatically increase the level of protein expression *E. coli*. Overexpression of proteins may
20 be harmful to the host cells. Consequently, host cell growth may be limited. The use of inducible promoter systems allows the host cells to be cultivated to acceptable densities prior to induction of gene expression, thereby facilitating higher product yields.

Various signal sequences may be used according to the invention. A signal sequence
25 which is homologous to the MHC coding sequence may be used. Alternatively, a signal sequence which has been selected or designed for efficient secretion and processing in the expression host may also be used. For example, suitable signal sequence/host cell pairs include the *B. subtilis* *sacB* signal sequence for secretion in *B. subtilis*, and the *Saccharomyces cerevisiae* α -mating factor or *P. pastoris* acid phosphatase *phoI* signal sequences for *P.*
30 *pastoris* secretion. The signal sequence may be joined directly through the sequence encoding the signal peptidase cleavage site to the protein coding sequence, or through a short nucleotide

bridge consisting of usually fewer than ten codons, where the bridge ensures correct reading frame of the downstream TCR sequence.

5 Elements for enhancing transcription and translation have been identified for eukaryotic protein expression systems. For example, positioning the cauliflower mosaic virus (CaMV) promoter 1000 bp on either side of a heterologous promoter may elevate transcriptional levels by 10- to 400-fold in plant cells. The expression construct should also include the appropriate translational initiation sequences. Modification of the expression construct to include a Kozak consensus sequence for proper translational initiation may increase the level of translation by
10 10 fold.

A selective marker is often employed, which may be part of the expression construct or separate from it (e.g., carried by the expression vector), so that the marker may integrate at a site different from the gene of interest. Examples include markers that confer resistance
15 to antibiotics (e.g., *bla* confers resistance to ampicillin for *E. coli* host cells, *nptII* confers kanamycin resistance to a wide variety of prokaryotic and eukaryotic cells) or that permit the host to grow on minimal medium (e.g., *HIS4* enables *P. pastoris* or His⁻ *S. cerevisiae* to grow in the absence of histidine). The selectable marker has its own transcriptional and translational initiation and termination regulatory regions to allow for independent expression of the marker.
20 If antibiotic resistance is employed as a marker, the concentration of the antibiotic for selection will vary depending upon the antibiotic, generally ranging from 10 to 600 µg of the antibiotic/mL of medium.

The expression construct is assembled by employing known recombinant DNA
25 techniques (Sambrook *et al.*, 1989; Ausubel *et al.*, 1999). Restriction enzyme digestion and ligation are the basic steps employed to join two fragments of DNA. The ends of the DNA fragment may require modification prior to ligation, and this may be accomplished by filling in overhangs, deleting terminal portions of the fragment(s) with nucleases (e.g., *ExoIII*), site directed mutagenesis, or by adding new base pairs by PCR. Polylinkers and adaptors may be
30 employed to facilitate joining of selected fragments. The expression construct is typically assembled in stages employing rounds of restriction, ligation, and transformation of *E. coli*.

Homologous recombination strategies can be used with co-electroporation of linear DNAs into yeast (see Fig. 9). Numerous cloning vectors suitable for construction of the expression construct are known in the art (λ ZAP and pBLUESCRIPT SK-1, Stratagene, LaJolla, CA; pET, Novagen Inc., Madison, WI; cited in Ausubel *et al.*, 1999) and the particular choice is not critical to the invention. The selection of cloning vector will be influenced by the gene transfer system selected for introduction of the expression construct into the host cell. At the end of each stage, the resulting construct may be analyzed by restriction, DNA sequence, hybridization and PCR analyses.

The expression construct may be transformed into the host as the cloning vector construct, either linear or circular, or may be removed from the cloning vector and used as is or introduced onto a delivery vector. The delivery vector facilitates the introduction and maintenance of the expression construct in the selected host cell type. The expression construct is introduced into the host cells by any of a number of known gene transfer systems (e.g., natural competence, chemically mediated transformation, protoplast transformation, electroporation, biolistic transformation, transfection, or conjugation) (Ausubel *et al.*, 1999; Sambrook *et al.*, 1989). The gene transfer system selected depends upon the host cells and vector systems used.

For instance, the expression construct can be introduced into *S. cerevisiae* cells by protoplast transformation or electroporation. Electroporation of *S. cerevisiae* is readily accomplished, and yields transformation efficiencies comparable to spheroplast transformation.

Monoclonal or polyclonal antibodies, preferably monoclonal, specifically reacting with a protein of interest may be made by methods known in the art. See, e.g., Harlow and Lane (1988) *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratories; Goding (1986) *Monoclonal Antibodies: Principles and Practice*, 2d ed., Academic Press, New York; and Ausubel *et al.* (1999) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc., New York.

MHC/peptide complexes of improved stability in cell-bound or soluble form which are characteristic of a particular neoplastic condition (cancer, tumor, or the like) or a particular virus infected cell or pathogen infected cell are useful, for example, as agonists of the immune system so that the neoplastic cell, virus infected cell or pathogen infected cell is more efficiently targeted for removal by T cells of the immune system. The improved MHC/p complexes can be labeled by joining, either covalently or noncovalently, a substance which provides a detectable signal. Suitable labels include but are not limited to radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, magnetic particles and the like. Additionally the MHC protein of the present invention can be coupled to a ligand for a second binding molecules: for example, the MHC protein can be biotinylated. Detection of the MHC protein or complex can be effected by binding of a detectable streptavidin (a streptavidin to which a fluorescent, radioactive, chemiluminescent, or other detectable molecule is attached or to which an enzyme for which there is a chromophoric substrate available). United States patents describing the use of such labels and/or toxic compounds to be covalently bound to the scTCR protein include but are not limited to Nos. 3,817,837; 3,850,752; 3,927,193; 3,939,350; 3,996,345; 4,277,437; 4,275,149; 4,331,647; 4,348,376; 4,361,544; 4,468,457; 4,444,744; 4,640,561; 4,366,241; RE 35,500; 5,299,253; 5,101,827; 5,059,413. Labeled MHC proteins or complexes can be detected using a monitoring device or method appropriate to the label used. Fluorescence microscopy or fluorescence activated cell sorting can be used where the label is a fluorescent moiety, and where the label is a radionuclide, gamma counting, autoradiography or liquid scintillation counting, for example, can be used with the proviso that the method is appropriate to the sample being analyzed and the radionuclide used. In addition, there can be secondary detection molecules or particle employed where there is a detectable molecule or particle which recognized the portion of the MHC protein which is not part of the binding site for the cognate TCR or other ligand or other ligand in the absence of a component as noted herein. The art knows useful compounds for diagnostic imaging in situ; see, e.g., U.S. Patent No. 5,101,827; 5,059,413. Radionuclides useful for therapy and/or imaging in vivo include ¹¹¹Indium, ⁸⁷Rubidium, ¹²⁵Iodine, ¹³¹Iodine, ¹²³Iodine, ⁶⁷Gallium, ⁹⁹Technetium. Toxins include diphtheria toxin, ricin and castor bean toxin, among others, with the proviso that once the TCR-toxin complex is bound to the cell, the toxic moiety is internalized so that it can exert its cytotoxic

effect. Immunotoxin technology is well known to the art, and suitable toxic molecules include, without limitation, chemotherapeutic drugs such as vindesine, antifolates, e.g. methotrexate, cisplatin, mitomycin, anthrocyclines such as daunomycin, daunorubicin or adriamycin, and cytotoxic proteins such as ribosome inactivating proteins (e.g., diphtheria toxin, pokeweed
5 antiviral protein, abrin, ricin, pseudomonas exotoxin A or their recombinant derivatives. See, generally, e.g., Olsnes and Pihl (1982) *Pharmac. Ther.* 25:355-381 and *Monoclonal Antibodies for Cancer Detection and Therapy*, Eds. Baldwin and Byers, pp. 159-179, Academic Press, 1985.

10 Table, high affinity MHC proteins specific for a particular ligand, e.g., a particular peptide, protein or cell type, are useful in diagnosing animals, including humans, believed to be suffering from a disease associated with the particular pMHC. The MHC molecules of the present invention are useful for detecting T cells that are specific for essentially any antigen, including, but not limited to, those associated with a neoplastic condition, an abnormal protein,
15 or an infection or infestation with a bacterium, a fungus, a virus, a protozoan, a yeast, a nematode or other parasite. Stable, high affinity MHC proteins specific for a particular ligand can also be used to induce the activity of T cells against antigens if desirable. For example, there are many peptides that have been associated with neoplastic cells, abnormal proteins, bacteria, fungi, a viruses, and protozoans whereby said peptides bind to a Class I MHC
20 protein. Stable, high affinity MHC proteins in complex with these peptides could serve as vaccines against the diseases by inducing T cell activity.

The high affinity MHC compositions can be formulated by any of the means known in the art. They can be typically prepared as injectables, especially for intravenous,
25 intraperitoneal or synovial administration (with the route determined by the particular disease) or as formulations for intranasal or oral administration, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid prior to injection or other administration may also be prepared. The preparation may also, for example, be emulsified, or the protein(s)/peptide(s) encapsulated in liposomes.

The active ingredients are often mixed with excipients or carriers which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients include but are not limited to water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. The concentration of the MHC protein in injectable, aerosol or nasal formulations is usually in the range of 0.05 to 5 mg/ml. Similar dosages can be administered to other mucosal surfaces.

In addition, if desired, vaccines may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include but are not limited to: aluminum hydroxide; N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP); N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP); N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE); and RIBI, which contains three components extracted from bacteria: monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL + TDM + CWS) in a 2% squalene/Tween 80 emulsion. Such additional formulations and modes of administration as are known in the art may also be used.

The stable high affinity MHC proteins of the present invention and/or pMHC-binding fragments having primary structure similar (more than 90% identity) to the high affinity MHC proteins and which maintain the high affinity for the cognate ligand may be formulated into vaccines as neutral or salt forms. Pharmaceutically acceptable salts include but are not limited to the acid addition salts (formed with free amino groups of the peptide) which are formed with inorganic acids, e.g., hydrochloric acid or phosphoric acids; and organic acids, e.g., acetic, oxalic, tartaric, or maleic acid. Salts formed with the free carboxyl groups may also be derived from inorganic bases, e.g., sodium, potassium, ammonium, calcium, or ferric hydroxides, and organic bases, e.g., isopropylamine, trimethylamine, 2-ethylamino-ethanol, histidine, and procaine. Alternatively, these stable high affinity MHC proteins can be used as antagonists of an interaction between endogenous MHC proteins of similar specificity and the cognate TCR cells.

High affinity MHC proteins or complexes for therapeutic use, e.g., those conjugated to cytotoxic compounds are administered in a manner compatible with the dosage formulation, and in such amount and manner as are prophylactically and/or therapeutically effective, according to what is known to the art. The quantity to be administered, which is generally in the range of about 100 to 20,000 μ g of protein per dose, more generally in the range of about 1000 to 10,000 μ g of protein per dose. Similar compositions can be administered in similar ways using labeled high affinity MHC proteins for use in imaging, for example, to detect deleterious cytotoxic T cells that are involved in autoimmune attacks and containing the cognate pMHCs. Precise amounts of the active ingredient required to be administered may depend on the judgment of the physician or veterinarian and may be peculiar to each individual, but such a determination is well within the skill of such a practitioner.

The vaccine or other immunogenic composition may be given in a single dose; two dose schedule, for example two to eight weeks apart; or a multiple dose schedule. A multiple dose schedule is one in which a primary course of vaccination may include 1 to 10 or more separate doses, followed by other doses administered at subsequent time intervals as required to maintain and/or reinforce the immune response, e.g., at 1 to 4 months for a second dose, and if needed, a subsequent dose(s) after several months. Humans (or other animals) immunized with the retrovirus-like particles of the present invention are protected from infection by the cognate retrovirus.

Standard techniques for cloning, DNA isolation, amplification and purification, for enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like, and various separation techniques are those known and commonly employed by those skilled in the art. A number of standard techniques are described in Sambrook et al. (1989) *Molecular Cloning*, Second Edition, Cold Spring Harbor Laboratory, Plainview, New York; Maniatis et al. (1982) *Molecular Cloning*, Cold Spring Harbor Laboratory, Plainview, New York; Wu (ed.) (1993) *Meth. Enzymol.* 218, Part I; Wu (ed.) (1979) *Meth. Enzymol.* 68; Wu et al. (eds.) (1983) *Meth. Enzymol.* 100 and 101; Grossman and Moldave (eds.) *Meth. Enzymol.* 65; Miller (ed.) (1972) *Experiments in Molecular Genetics*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Old and Primrose (1981) *Principles of Gene*

Manipulation, University of California Press, Berkeley; Schleif and Wensink (1982) *Practical Methods in Molecular Biology*; Glover (ed.) (1985) *DNA Cloning* Vol. I and II, IRL Press, Oxford, UK; Hames and Higgins (eds.) (1985) *Nucleic Acid Hybridization*, IRL Press, Oxford, UK; and Setlow and Hollaender (1979) *Genetic Engineering: Principles and Methods*, Vols. 1-4, Plenum Press, New York. Abbreviations and nomenclature, where employed, are deemed standard in the field and commonly used in professional journals such as those cited herein.

All references cited in the present application are incorporated by reference herein to supplement the disclosure and experimental procedures provided in the present Specification to the extent that there is no inconsistency with the present disclosure.

The following examples are provided for illustrative purposes, and are not intended to limit the scope of the invention as claimed herein. Any variations in the exemplified articles and/or methods which occur to the skilled artisan are intended to fall within the scope of the present invention.

EXAMPLES

Example 1. Fusion of the MHC α chain to the $\beta 2m$ in the Yeast Display Vector pCT302

The mouse MHC K^b α chain was fused to the mouse $\beta 2m$ [Mottez et al. (1995) *J. Exp. Med.* 181(2), 493-502]. The K^b gene was PCR amplified using primers with *Nhe* I and *Afl* II restriction sites. The 5' primer contained a 30 bp linker upstream of the K^b gene and the 3' primer contained a 45 bp connecting linker (underlined) downstream of the gene (5' CAA TGG CTA GCG GTG GAC TTA AGG GTG GAC CAG GTG GAG GTT CAG GAG GTG GAG GCC CAC ACT CGC TGA GGT ATT TCG T 3', SEQ ID NO:7; and 5' TGA ACC TCC GCC TCC TGA TCC ACC GCC ACC TGA ACC TAT TCC ACC CTC CCA TCT CAG GGT GAG GGG CTC AGG 3', SEQ ID NO. 8). The $\beta 2m$ gene was PCR amplified with the 5' primer containing the overlapping 45 bp linker (underlined) upstream and the 3' primer containing a c-myc epitope tag and unique *Xho* I site downstream of the $\beta 2m$ (5' GGT GGA ATA GGT TCA GGT GGC GGT GGA TCA GGA GGC GGA GGT TCA ATC CAG AAA ACC CCT CAA ATT CAA GTA T 3', SEQ ID NO:9, and 5' GTT CCC TCG AGC TAT

TAC AAG TCT TCT TCA GAA ATA AGC TTT TGT TCC ATG TCT CGA TCC CAG
TAG ACG GT 3', SEQ ID NO:10). Using PCR "sewing" of the overlapping linker [Davis
et al. (1992) *Biotechnology* 9(2), 165-169], an amplified K^b/β2m fusion was generated using both
the K^b and β2m PCR products, primers 1 and 4 and TaqPlus Precision PCR System
5 (Stratagene, La Jolla, CA). The L^d/β2m MHC gene was fused and PCR amplified in an
analogous manner. The K^b/β2m and L^d/β2m PCR products were digested with *Nhe* I/*Xho* I and
ligated into the yeast surface display vector pCT302 containing a nine-residue epitope tag (HA)
and the AGA2 open reading frame downstream of the inducible GAL1 promoter [Boder and
Wittrup (1997) *supra*].

10

Example 2. Peptide/MHC Construction.

The AGA2 gene was cloned at the COOH terminus of the peptide/K^b/β2m gene in order
to allow a free NH₂ terminus of the peptide. First, the K^b/β2m signal sequence was PCR
amplified with *Eco*RI and *Nhe* I restriction sites upstream and downstream of the signal
15 sequence (SS) (5' TCT CAA GAA TTC TAC TTC ATA CAT TTT 3', SEQ ID NO:11; and
5' GTA TCT GCT AGC TGC TAA AAC TGA AGC 3', SEQ ID NO:12). The SS PCR
product was digested *Nhe* I/*Eco*RI and ligated into the *Nhe* I/*Eco*RI digested pCT302 vector.
The resulting plasmid contained the SS but not the AGA2 gene. Secondly, a SIYRYYYGL
(SEQ ID NO:1) (SIYR)/K^b/β2m PCR product was generated with a SIYR encoded primer
20 (underlined) (5' ATA CTA GCT AGC TTG GAT AAA AGG TCT ATT TAT AGA TAT
TAT GGT TTG CTT AAG GGT GGA CCA GGT GGA GGT 3', SEQ ID NO:13; and 5'
CAA TCC AGA TCT TTA CTA ATG CAA GTC TTC TTC AGA AAT AAG 3', SEQ ID
NO:14). *Nhe* I and *Nde* I restriction sites are located in the upstream and downstream primers
respectively. The SIYR/K^b/β2m PCR product was digested with *Nhe* I and *Nde* I and ligated
25 into the *Nhe* I/*Nde* I digested pCT302 SS vector (now called SS-SIYR K^b pCT302). Finally,
AGA2 was PCR amplified (5' GGA TAT CAT ATG CAG GAA CTG ACA ACT ATA3',
SEQ ID NO:15, and 5' ATT TGC AGA TCT CGA GTT ACT AAG CGT AGT CTG GAA
CGT CGT A 3', SEQ ID NO:16), digested with *Nde* I and *Xho* I and ligated into the *Nde*
I/*Xho*I digested SS-SIYR K^b pCT302. The resulting construct contained the following order
30 of genes in the pCT302 backbone: SS-SIYR K^b/β2m-AGA2.

Example 3. OVA and dEV8 Peptide Loading.

The sense and anti-sense oligonucleotide sequences for both OVA (SIINFEKL, SEQ ID NO:2) and dEV8 (EQYKFYSV, SEQ ID NO:5) with a *Nhe* I and *Afl* II site upstream and downstream respectively were each phosphorylated with T4 DNA kinase (OVA 5' CT AGC TTG GAT AAA AGG AGC ATC ATC AAT TTT GAA AAG CTT C3', SEQ ID NO:17; and 5'TT AAG AAG CTT TTC AAA ATT GAT GAT GCT CCT TTT ATC CAA G3', SEQ ID NO:18; dEV8 5' CT AGC TTG GAT AAA AGG GAA CAA TAC AAA TTC TAC TCA GTT C3', SEQ ID NO:19; and 5'TT AAG AAC TGA GTA GAA TTT GTA TTG TTC CCT TTT ATC CAA G3', SEQ ID NO:20). The sense and anti-sense phosphorylated oligonucleotides were mixed (400 pmol), heated at 100°C for 1 min and cooled slowly. Phosphorylated peptide cassettes were ligated into *Nhe* I/*Afl* II digested SIYR/K^b/β2m pCT302. Ligation reactions were transformed into DH10B electrocompetent *E. coli* cells and plated on LB/amp and incubated for 15 hrs at 37 °C. Transformants were screened, and positive clones were sequenced. The resulting plasmids contained OVA and dEV8 tethered to K^b/β2m.

Example 4. Transformation into Yeast.

The resultant MHC nucleotide constructs were transformed by the lithium acetate (LiAc) transformation method [Geitz et al. (1995) *Yeast* 11, 355-360] into the *S. cerevisiae* strain BJ5465 (α *ura3-52 trp1 leu2Δ1 his3Δ200 pep4::HIS2 prbΔ1.6 can1 GAL*; Yeast Genetic Stock Center, Berkeley, CA) containing a chromosomally integrated AGA1 coding sequence expressed under the control of the GAL1 promoter (strain EBY100; Boder and Wittrup (1997) *supra*).

Example 5. Induction and Detection of MHC on the Yeast Surface.

Yeast cells transformed with pCT302/MHC plasmid constructs were grown overnight at 30 °C with shaking in 2 mL selective glucose medium SD-CAA (glucose 2 wt %, Difco yeast nitrogen base 0.67 wt %, casamino acids 0.5 wt %). After 18-24 hours, recombinant AGA1 + AGA2-MHC I expression was induced at 20°C with shaking in 5 mL selective galactose medium (SG-CAA, where 2% galactose replaces the glucose in SD-CAA). Cultures were harvested after 24-48 hours (1-2 doublings) by centrifugation, washed with PBS (10 mM NaPO₄, 150 mM NaCl, pH 7.3) containing 0.5% bovine serum albumin and incubated 45

minutes on ice with 25 μ L of an anti-MHC antibody, anti-c-myc Mab 9E10 (1:100 dilution of raw ascites fluid; Berkeley Antibody Co., Richmond, CA), or anti-HA Mab 12CA5 (10 μ g/ml. Boehringer Mannheim, Indianapolis, IN). Cells were washed with PBS and incubated 30 minutes on ice with either FITC-labeled F(ab')₂ goat anti-mouse IgG (1:50; Kirkegaard and Perry Labs, Inc., Gaithersburg, MD) or a streptavidin-phycoerythrin (SA-PE) conjugate (1:200; PharMingen, San Diego, CA). Labeled yeast cells were analyzed on a Coulter Epics XL flow cytometer. Data for 10,000-20,000 events were collected, and the population was gated according to light scatter (size) to prevent analysis of cell clumps.

10 Example 6. Random Mutagenesis of dEV8/K^b/β2m and SIYR/K^b/β2m.

dEV8/K^b/β2m and SIYR/K^b/β2m genes were randomly mutagenized using a PCR error prone technique. dEV8/K^b/β2m and SIYR/K^b/β2m were PCR amplified using vector specific primers at least 50 bp upstream and downstream of each gene with PCR conditions that cause random mutations to be inserted by Taq polymerase (GIBCO/BRL, Invitrogen, Carlsbad, CA). At a Mn:Mg ratio of about 0.16:1, the polymerase is more susceptible to inserting a random nucleotide during elongation. Using homologous recombination [Raymond et al. (1999) *Biotechniques* 26(1): 134-138, 140-141], the dEV8/K^b/β2m and SIYR/K^b/β2m pCT302 vectors digested with *Nhe* and *Nde*I were combined with the error prone PCR products and electroporated (Bio-Rad Gene-Pulser II, 1.5V, 25 μ F, 0.2cm gene pulser cuvettes) into 40 μ L of electrocompetent *S. cerevisiae* cells (BJ5465, strain EBY100). The resulting transformations (separately for the two chimeric genes) are pooled, and a dilution is plated on SD-CAA plates. Plates are incubated at 30 C for 3 days, and the library size is tabulated.

Example 7. Cell Sorting.

25 The yeast library was grown in SD-CAA (2% dextrose, 0.67% yeast nitrogen base, 1% Casamino acids (Difco, Detroit, MI)) at 30 C to an OD₆₀₀=4.0. To induce surface scTCR expression, yeast cells were pelleted by centrifugation, resuspended to an OD₆₀₀=1.0 in SG-CAA (2% galactose, 0.67% yeast nitrogen base, 1% casamino acids), and incubated at 20 C for 48 hr. In general, 10⁷ cells/tube were incubated on ice for 1 hr with 50 μ L of biotinylated anti-K^b antibody (B.8.24.3) diluted in phosphate buffered saline (pH 7.4) supplemented with 0.5 mg/ml BSA (PBS-BSA). After incubation, cells were washed and

labeled for 30 min with SA:PE in PBS-BSA. Yeast cells were then washed and resuspended in PBS-BSA immediately prior to sorting. Cells exhibiting the highest fluorescence were isolated by FACS sorting with a Coulter 753 bench. After isolation, sorted cells were expanded in SD-CAA and induced in SG-CAA for subsequent rounds of selection. Three sequential sorts were performed for each mutant preparation with increasingly dilute anti-K^b. The percentages of total cells isolated from each sort were 1.0, 0.25 and 0.1%, respectively. Aliquots of the third sorts were plated on SD-CAA to isolate individual clones, which were then analyzed by flow cytometry using a Coulter Epics XL instrument. The clones with the highest fluorescence have their DNA rescued with the Zymoprep Yeast Plasmid Miniprep Kit (Zymogen Research, Orange, CA). The DNA is retransformed into DH10 Belectrocompetent *E. coli*, mini prepped and submitted for sequencing. The sequences are analyzed, and the mutations are located.

Table 1.
Comparison of Properties of H-2K^b, H-2D^b and H-2 L^d Proteins

	H-2K ^b	H-2D ^b	H-2L ^d
Heavy chain-B2m			
vdw	17	24	7
H bonds	7	13	10
alpha 1/ alpha2 : B2m			
vdw	13	16	4
H bonds	4	5	2
alpha 3:B2m			
vdw	4	8	3
H bonds	3	8	8

Table 2.
Various Single-Chain Class I MHC Constructions
Cloned in pCT302 Yeast Display Vector

5 Nucleic Acid Sequence 1: SS-AGA2-K^b/β2m-c-myc (SEQ ID NO:22)

ATGCAGTTACTTCGCTGTTTTTCAATATTTTCTGTTATTGCTTCAGTTTTAGC
ACAGGAACTGACAACTATATGCGAGCAAATCCCCTCACCAACTTTAGAATCGA
CGCCGTACTCTTTGTCAACGACTACTATTTTGGCCAACGGGAAGGCAATGCAA
10 GGAGTTTTTTGAATATTACAAATCAGTAACGTTTGTGAGTAATTGCGGTTCTCA
CCCCTCAACAACTAGCAAAGGCAGCCCCATAAACACACAGTATGTTTTTAAGG
ACAATAGCTCGACGATTGAAGGTAGATACCCATACGACGTTCCAGACTACGCT
CTGCAGGCTAGTGGTGGTGGTGGTCTGGTGGTGGTGGTCTGGTGGTGGTGG
TTCTGCTAGCGGTGGACTTAAGGGTGGACCAGGTGGAGGTTTCAGGAGGTGGAG
15 GCCCACACTCGCTGAGGTATTTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGG
GAGCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTT
CGACAGCGACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGC
AGGAGGGGCCCGAGTATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAATGAG
CAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGGCTACTACAACCAGAGCAA
20 GGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGGGGTCCGACG
GGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTACATC
GCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCTGAT
CACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCTACC
TGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGAAGAACGGGAACGCG
25 ACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACAGCAGACC
TGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCTGACA
TCACCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACATGGAGCTT
GTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGT
GGTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGGGGC
30 TGCCTGAGCCCCCTCACCCTGAGATGGGAGGGTGAATAGGTTTCAGGTGGCGGT
GGATCAGGAGGCGGAGGTTCAATCCAGAAAACCCCTCAAATTCAGGTATACTC
ACGCCACCCACCGGAGAATGGGAAGCCGAACATACTGAACTGCTACGTAAACAC
AGTTCCACCCGCCTCACATTGAAATCCAAATGCTGAAGAACGGGAAAAAATT
CCTAAAGTAGAGATGTCAGATATGTCCTTCAGCAAGGACTGGTCTTTCTATAT
35 CCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATACGCCTGCAGAG
TTAAGCATGACAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACATG
GAACAAAAGCTTATTTCTGAAGAAGACTTGTAATAGCTCGAG

40

Amino Acid Sequence 1: SS-AGA2-K^b/β2m-c-myc (SEQ ID NO:23)

5 MQLLRCSIFSVIASVLAQELTTICEQIPSPITLESTPYSLSSTTTILANGKAMQ
GVFEYYKSVTFVSNCGSHPSSTTSKGSPINTQYVFKDNSSTIEGRYPYDVPDYA
LQASGGGGSGGGGSGGGGSASGGLKGGPGGGSGGGGPHSLRYFVTAVSRPGLG
EPRYMEVGYYDDTEFVRFDSDAENPRYEPRARWMEQEGPEYWERETQKAKGNE
QSFRVDLRTLGLYYNQSKGGSHTIQVISGCEVGS DGRLLRGYQQYAYDGC DYI
ALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGT CVEWLRRYLKNGNA
10 TLLRTDSPKAHVTHHSRPEDKVT LRCWALGFYPADITLTWQLNGEELIQDMEL
VETRPAGDGT FQK WASVVVPLGKEQYYTCHVYHQGLPEPLTLRWEGGIGSGGG
GSGGGGSIQKTPQIQVYSRHPPE NGKPNILNCYVTQFHPPHIEIQMLKNGKKI
PKVEMSDMSFSKDWSFYILAHTFTPTETDTYACRVKHD SMAEPKTVYWDRDM
EQKLISEEDL**LE

15 Nucleic Acid Sequence 2: SS-SIYR/K^b/β2m-c-myc-AGA2 (SEQ ID NO:24)

GAATTCTACTTCATACATTTTCAATTAAGATGCAGTTACTTCGCTGTTTTTCA
ATATTTTCTGTTATTGCTTCAGTTTTAGCAGCTAGCTTGGATAAAAGATCTAT
20 TTATAGATATTATGGTTTGCTTAAGGGTGGACCAGGTGGAGGTTTCAGGAGGTG
GAGGCCACACTCGCTGAGGTATTTTCGT CACCGCCGTGTCCCGGCCCGGCCTC
GGGGAGCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCG
CTTCGACAGCGACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGG
AGCAGGAGGGGGCCCGAGTATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAAT
25 GAGCAGAGTTTCCGAGTGGACCTGAGGACCTGCTCGGCTACTACAACCAGAG
CAAGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGGGGTCCG
ACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTAC
ATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCT
GATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCT
30 ACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGAAGAACGGGAAC
GCGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACAGCAG
ACCTGAAGATAAAGTCACCTGAGGTGCTGGGGCCCTGGGCTTCTACCCTGCTG
ACATCACCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACATGGAG
CTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGT
35 GGTGGTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGG
GGCTGCCTGAGCCCCTCACCTGAGATGGGAGGGTGGAAATAGGTTTCAGGTGGC
GGTGGATCAGGAGGCGGAGGTTCAATCCAGAAAACCCCTCAAATTC AAGTATA
CTCACGCCACCCACCGGAGAATGGGAAGCCGAACATACTGAACTGCTACGTAA
CACAGTTCCACCCGCCTCACATTGAAATCCAAATGCTGAAGAACGGGAAAAAA
40 ATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGCAAGGACTGGTCTTTCTA

TATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATACGCCTGCA
GAGTTAAGCATGACAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGAC
ATGGAACAAAAGCTTATTTCTGAAGAAGACTTGCATATGCAGGAAGTACAAAC
TATATGCGAGCAAATCCCCTCACCAACTTTAGAATCGACGCCGTACTCTTTGT
5 CAACGACTACTATTTTGGCCAACGGGAAGGCAATGCAAGGAGTTTTTGAATAT
TACAAATCAGTAACGTTTGTGAGTAATTGCGGTTCTCACCCCTCAACAACTAG
CAAAGGCAGCCCCATAAACACACAGTATGTTTTTAAGGACAATAGCTCGACGA
TTGAAGGTAGATACCCATACGACGTTCCAGACTACGCTTAGTAAGTACGAG

10

Amino Acid Sequence 2: SS-SIYR/K^b/β2m-c-myc-AGA2 (SEQ ID NO:25)

ILLHTFSIKMQLLRCSIFSIVASVLAASLDKRSIYRYYGLLKGGPGGGSGGG
GPHSLRYFVTAVSRPGLGEPYMEVGYVDDTEFVRFDSDAENPRYEPRARWME
15 QEGPEYWERETQKAKGNEQSFVRDLRLTLLGYYNQSKGGSHTIQVISGCEVGSD
GRLLRGYQQYAYDGC DYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAY
LEGTCVEWLRRLKNGNATLLRTDSPKAHVTHHSRPEDKVTLCWALGFYPAD
ITLTWQLNGEELIQDMELVETRPAGDGTQKQWASVVVPLGKEQYYTCHVYHQG
LPEPLTLRWEGGIGSGGGSGGGSGSIQKTPQIQVYSRHPPENGKPNILNCYVT
20 QFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTFTPTETDTYACR
VKHDSMAEPKTVYWDRDMEQKLISEEDLHMQLTICEQIPSPITLESTPYSLS
TTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPIQYVFKDNSSTI
EGRYPYDVPDYA

25

Nucleic Acid Sequence 3: SS-dEV8/K^b/β2m-c-myc-AGA2 (SEQ ID NO:26)

GAATTCTACTTCATACATTTTCAATTAAGATGCAGTTACTTCGCTGTTTTTCA
ATATTTTCTGTTATTGCTTCAGTTT TAGCAGCTAGCTTGGATAAAAGAGAACA
30 ATACAAATTCTACTCAGTTCTTAAGGGTGGACCAGGTGGAGGTT CAGGAGGTG
GAGGCCCACACTCGCTGAGGTATTTCTGTCACCGCCGTGTCCCGGCCCGGCCTC
GGGGAGCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCG
CTTCGACAGCGACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGG
AGCAGGAGGGGGCCCGAGTATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAAT
35 GAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGGCTACTACAACCAGAG
CAAGGGCGGCTCTCACACTATT CAGGTGATCTCTGGCTGTGAAGTGGGGTCCG
ACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTAC
ATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCT
GATCACCAAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCT
40 ACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGAAGAACGGGAAC

GCGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACAGCAG
ACCTGAAGATAAAGTCACCCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCTG
ACATCACCCCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACATGGAG
CTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGT
5 GGTGGTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGG
GGCTGCCTGAGCCCCCTCACCCCTGAGATGGGAGGGTGGGAATAGGTTTCAGGTGGC
GGTGGATCAGGAGGCGGAGGTTCAATCCAGAAAACCCCTCAAATTCAGGTATA
CTCACGCCACCCACCGGAGAATGGGAAGCCGAACATACTGAACTGCTACGTAA
CACAGTTCCACCCGCCTCACATTGAAATCCAAATGCTGAAGAACGGGAAAAAA
10 ATTCCTAAAGTAGAGATGTCAGATATGTCTTCAGCAAGGACTGGTCTTTCTA
TATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATACGCCTGCA
GAGTTAAGCATGACAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGAC
ATGGAACAAAAGCTTATTTCTGAAGAAGACTTGCATATGCAGGAACTGACAAC
TATATGCGAGCAAATCCCTCACCAACTTTAGAATCGACGCCGTACTCTTTGT
15 CAACGACTACTATTTTGGCCAACGGGAAGGCAATGCAAGGAGTTTTTGAATAT
TACAAATCAGTAACGTTTGTGAGTAATTGCGGTTCTCACCCCTCAACAACTAG
CAAAGGCAGCCCCATAAACACACAGTATGTTTTTAAGGACAATAGCTCGACGA
TTGAAGGTAGATACCCATACGACGTTCCAGACTACGCTTAGTAACTCGAG

20 Amino Acid Sequence 3: SS-dEV8/K^b/β2m-c-myc-AGA2 (SEQ ID NO:27)

ILLHTFSIKMQLLRCSIFSIVIASVLAASLDKREQYKFYSVLKGGPGGGSGGG
GPHSLRYFVTVSRPGLGEPRYMEVG YVDDTEFVRFDSDAENPRYEPRARWME
25 QEGPEYWERETQKAKGNEQSFRVDLRTL LGYYNQSKGGSHTIQVISGCEVGS
GRLLRGYQQYAYDGDYIALNEDLKTWTAADMAALITKHKEQAGEAERL RAY
LEGTCVEWLRRYLKNGNATLLRTDSPKAHVTHHSRPEDKVT LRCWALGFYPAD
ITLTWQLNGEELIQDMELVETRPA GDGTFQKWASVVVPLGKEQYYTCHVYHQ
LPEPLTLRWE GGIGSGGGGSGGGGSIQKTPQIQVYSRHPPENGKPNILNCYVT
30 QFHPPHIEIQMLKNGKKIPKVMSDMSFSKDWSFYILAHTFTPTETDTYACR
VKHDSMAEPKTVYWD RDMEQKLI SEEDLHMQELTTICEQIPSP TLESTPYSLS
TTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPI NTQYVFKDNSSTI
EGRYPYDV PDYA

35 Nucleic Acid Sequence 4: SS-OVA/K^b/β2m-c-myc-AGA2 (SEQ ID NO: 28)

GAATTCTACTTCATACATTTTCAATTAAGATGCAGTTACTTCGCTGTTTTTCA
ATATTTTCTGTTATTGCTTCAGTTTTAGCAGCTAGCTTGGATAAAAGGAGCAT
40 CATCAATTTTGAAAAGCTTCTTAAGGGTGGACCAGGTGGAGGTT CAGGAGGTG

GAGGCCACACTCGCTGAGGTATTTTCGTCACCGCCGTGTCCCGGCCCGGCCTC
GGGGAGCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCG
CTTCGACAGCGACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGG
AGCAGGAGGGGGCCCGAGTATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAAT
5 GAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGGCTACTACAACCAGAG
CAAGGGCGGCTCTCACACTATTTCAGGTGATCTCTGGCTGTGAAGTGGGGTCCG
ACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTAC
ATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCT
GATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCT
10 ACCTGGAGGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGAAGAACGGGAAC
GCGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACAGCAG
ACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCTG
ACATCACCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACATGGAG
CTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGT
15 GGTGGTGCCTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGG
GGCTGCCTGAGCCCCTCACCTGAGATGGGAGGGTGAATAGGTTTCAAGTGGC
GGTGGATCAGGAGGCGGAGGTTCAATCCAGAAAACCCCTCAAATTCAAGTATA
CTCACGCCACCCACCGGAGAATGGGAAGCCGAACATACTGAACTGCTACGTAA
CACAGTTCCACCCGCTCACATTGAAATCCAAATGCTGAAGAACGGGAAAAAA
20 ATTCCTAAAGTAGAGATGTCAGATATGTCCTTCAGCAAGGACTGGTCTTTCTA
TATCCTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATACGCCTGCA
GAGTTAAGCATGACAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGAC
ATGGAACAAAAGCTTATTTCTGAAGAAGACTTGCATATGCAGGAAGTACAAAC
TATATGCGAGCAAATCCCTCACCAACTTTAGAATCGACGCCGTAATCTTTGT
25 CAACGACTACTATTTTGGCCAACGGGAAGGCAATGCAAGGAGTTTTTGAATAT
TACAAATCAGTAACGTTTGTGAGTAATTGCGGTTCTCACCCCTCAACAAC TAG
CAAAGGCAGCCCCATAAACACACAGTATGTTTTTAAGGACAATAGCTCGACGA
TTGAAGGTAGATACCATAACGACGTTCCAGACTACGCTTAGTAACTCGAG

30 Amino Acid Sequence 4: SS-OVA/K^b/β2m-c-myc-AGA2 (SEQ ID NO:29)

ILLHTFSIKMQLLRCSIFSVIASVLAASLDKRSIINF EKLLKGGPGGGSGGG
GPHSLRYFVTAVSRPGLGEPRYMEVG YVDDTEFVRFDSDAENPRYEPRARWME
35 QEGPEYWERETQKAKGNEQSFRVDLRTL LGYYNQSKGGSHTIQVISGCEVGS D
GRLLRGYQQYAYDGC DYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAY
LEGT CVEWLRRLYLKNGNATLLRTDSPKAHVTHHSRPEDKVTLRCWALGFYPAD
ITLTWQLNGEELIQDMELVETRPA GDGTFQKWASVVVPLGKEQYYTCHVYHQG
LPEPLTLRWE GGI GSGGGGSGGGGSIQKTPQIQVYSRHPPE NGKPNILNCYVT
40 QFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTFTPETDTYACRV

KHDSMAEPKTVYWDRDMEQKLISEEDLHMQELTTICEQIPSPITLESTPYSLSST
TTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPIINTQYVFKDNSSTIE
GRYPYDVPDYA

5

Nucleic Acid Sequence 5: SS-AGA2-L⁴/β2m-c-myc (SEQ ID NO:30)

10

15

20

25

30

35

40

ATGCAGTTACTTCGCTGTTTTTCAATATTTTCTGTTATTGCTTCAGTTTTAGC
ACAGGAACTGACAACTATATGCGAGCAAATCCCCTCACCAACTTTAGAATCGA
CGCCGTACTCTTTGTCAACGACTACTATTTTGGCCAACGGGAAGGCAATGCAA
GGAGTTTTTTGAATATTACAAATCAGTAACGTTTGTGAGTAATTGCGGTTCTCA
CCCCTCAACAACCTAGCAAAGGCAGCCCCATAAACACACAGTATGTTTTTAAGG
ACAATAGCTCGACGATTGAAGGTAGATACCCATACGACGTTCCAGACTACGCT
CTGCAGGCTAGTGGTGGTGGTGGTTCGGTGGTGGTGGTCTGGTGGTGGTGGT
TCTGCTAGCGGTGGACTTAAGGGTGGACCAGGTGGAGGTTGAGGAGGTGGAGG
CCCACACTCGATGCGGTATTTTCGAGACCGCGGTGTCCCGGCGCGGCCTCGGGG
AGCCCCGGTACATCTCTGTCTGGCTATGTGAACGACAAGGAGTTCGTGCGCTTC
GACAGCGACGCGGAGAATCCGAGATATGAGCCGAGGGGCGCCGTGGATGGAGCA
GGAGGGGCGCGAGTATTGGGAGCGGATCACGCAGATCGCCAAGGGCCAGGAGC
AGTGGTTCGAGTGAACCTGAGGACCTGCTCGGCTACTACAACCAGAGCGCG
GGCGGCACTCACACACTCCAGTGGATGTACGGCTGTGACGTGGGGTTCGGACGG
GCGCCTCCTCCGCGGGTACGAGCAGTTCGCCTACGACGGCTGCGATTACATCG
CCCTGAACGAAGACCTGAAAACGTGGACGTTTCGCGGACATGTCGTGATGATC
ACCCGACGCAAGTGGGAGCAGGCTGGTGTGTCAGAGTATTACAGGGCCTACCT
GGAGGGCGAGTGCCTGGAGTGGCTCCACAGATACCTGAAGAACGGGAATGCTA
CGCTGCTGCGCACAGATTCCCCAAGGCACATGTGACCTATCACCCAGATCT
AAAGGTGAAGTCACCCTGAGGTGCTGGGCGCTGGGCTTCTACCCTGCTGACAT
CACCTGACCTGGCAGTTGAATGGGGAGGAGCTGACCCAGGACATGGAGCTTG
TGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTG
GTGCCTCTTGGGAAGGAGCAGAATTACACATGCCGTGTGTACCATGAGGGGCT
GCCCCATCCCCCTCACCTGAGATGGGAGGGTGGGAATAGGTTGAGGTGGCGGTG
GATCAGGAGGCGGAGGTTCAATCCAGAAAACCCCTCAAATTCAGTATACTCA
CGCCACCCACCGGAGAATGGGAAGCCGAACATACTGAACTGCTACGTAAACA
GTTCCACCCGCTCACATTGAAATCCAAATGCTGAAGAACGGGAAAAAATTC
CTAAAGTAGAGATGTCAGATATGTCCTTCAGCAAGGACTGGTCTTTCTATATC
CTGGCTCACACTGAATTCACCCCCACTGAGACTGATACATACGCCTGCAGAGT
TAAGCATGACAGTATGGCCGAGCCCAAGACCGTCTACTGGGATCGAGACATGG
AACAAAAGCTTATTTCTGAAGAAGACTTGTAATAGCTCGAG

Amino Acid Sequence 5: SS-AGA2-L⁴/β2m-c-myc (SEQ ID NO:31)

5 MQLLRCSFISFVIA SVLAQELTTICEQIPSP TLESTPYSLSTTTILANGKAMQ
GVFEYYKSVTFVSNCGSH PSTTSKGSPI NTQYVFKDNSSTIEGRYPYDVPDYA
LQASGGGGSGGGGSGGGGSASGGLKGGPGGGSGGGGPHSMRYFETAVSRRGLG
EPRYISVG YVNDKEFVRFDSDAENPRYEPRAPWMEQEGPEYWERITQIAKGQE
QWFRVNLRTLLGYYNQ SAGGTHTLQW MYGCDVGS DGRLLR GYEQFAYD GCDYI
ALNEDLKTWTFAD MSSMITRRKWEQAGAAEYRAYLEGECEV EWLHRYLKNGNA
TLLRTDSPKAHV TYHPRSKGEVTLRCWALGFYPADITLTWQLNGEELTQDMEL
10 VETRPAGDGT FQK WASVVVPLGKEQNYTCRVYHEGLPHPLTLRWEGGIGSGGG
GSGGGGSIQKTPQIQVYSRHPPENGKPNILNCYVTQFHPPHIEIQMLKNGKKI
PKVEMSDMSFSKDWSFYILAHT EFTP TETDTYACRVKHDSMAEPKTVYWRDM
EQKLISEEDL

Table 3.

Sequences of mutant clones isolated by sorting from
dEV8/Kb error-prone PCR library.

20 Nucleic Acid Sequence 1: dEP.1 (SEQ ID NO:32)

GAATTCTACTTCATACATTTTCAATTAAGATGCAGTTACTTCGCTGTTTTTCA
ATATTTTCTGTTATTGCTTCAGTTTTAGCAGCTAGCTTGGATAAAAGAGAACA
ATACAAATTCTACTCAGTTCTTAAGGGTGGACCAGGTGGAGGTTTCAGGAGGTG
25 GAGGCCACACTCGCTGAGGTATTTCTGTCACCGCCGTGTCCCGGCCCGGCCTC
GGGGAGCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCG
CTTCGACAGCGACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGG
AGCAGGAGGGGCCCGAGTATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAAT
GAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGGCTACTACAACCAGAG
30 CAAGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGGGGTCCG
ACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTAC
ATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCT
GATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCT
ACCTGGAGGGCACGTGCGTGGAGAGGCTCCGCAGATACCTGAAGAACGGGAAC
35 GCGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACAGCAG
ACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCTG
ACATCACCTGACCTGGCAGTTGAATGGGGAGGAGCT

Amino Acid Sequence 1: dEP.1 (SEQ ID NO:33)

ILLHTFSIKMQLLRCSIFSIVIASVLAASLDKREQYKFYSVLKGGPGGGSGGG
GPHSLRYFVTAVSRPGLGEPRYMEVG YVDDTEFVRFDSDAENPRYEPRARWME
5 QEGPEYWERETQKAKGNEQSFRVDLRTL LGYNNQSKGGSHTIQVISGCEVGS
GRLLRGYQQYAYDGC DYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAY
LEGTCVERLRRYLKNGNATLLRTDSPKAHVTHHSRPEDKVTLRCWALGFYPAD
ITLTWQLNGEELIQDMELVETRPAGDGT FQKWASVVVPLGKEQYYTCHVYHQG
LPEPLTLRWE GGI GSGGGGSGGGGSIQKTPQIQVYSRHPPENGKPNILNCYVT
10 QFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFNILAHTEFTPTETDTYACR
VKHDSMAEPKTVYWD RDMEQRLISEEDLHMQELTTICEQIPSP TLESTPYSL
TTTILANGKAMQGVFEYYKSVTFVSNC GSH PSTTSK GSPINTQYVFKDNSSTI
EGRYPYDVPDYA

15

Nucleic Acid Sequence 2: dEP.3 (SEQ ID NO:34)

GAATTCTACTTCATACATTTTCAATTAAGATGCAGTTACTTCGCTGTTTTTCA
ATATTTTCTGTTATTGCTTCAGTTTTAGCAGCTAGCTTGGATAAAAGAGAACA
20 ATACAAATTCTACTCAGTTCTTAAGGGTGGACCAGGTGGAGGTTTCAGGAGGTG
GAGGCCACACTCGCTGAGGTATTTCTGCACCGCCGTGTCCCGGCCCGGCCTC
GGGGAGCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTTCGTGCG
CTTCGACAGCGACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGG
AGCAGGAGGGGCGGAGTATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAAT
25 GAGCAGAGTTTCCGAGTGGACCTGAGGACCTGCTCGGCTACTACAACCAGAG
CAAGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGGGGTCCG
ACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTAC
ATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCT
GATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCT
30 ACCTGGAGGGCACGTGCGTGGAGCGGCTCCGCAGATACCTGAAGAACGGGAAC
GCGACGCTGCTGCGCACAGATTCCCAAAGG

35

Amino Acid Sequence 2: dEP.3 (SEQ ID NO:35)

ILLHTFSIKMQLLRCSIFSIVIASVLAASLDKREQYKFYSVLKGGPGGGSGGG
GPHSLRYFVTAVSRPGLGEPRYMEVG YVDDTEFVRFDSDAENPRYEPRARWME
QEGPEYWERETQKAKGNEQSFRVDLRTL LGYNNQSKGGSHTIQVISGCEVGS
GRLLRGYQQYAYDGC DYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAY
40 LEGTCVERLRRYLKNGNATLLRTDSPKAHVTHHSRPEDKVTLRCWALGFYPAD

ITLTWQLNGEELIQDMELVETRPAGDGTFOKWASVVVPLGKEQYYTCHVYHQG
LPEPLTLRWEGGIGSGGGGSGGGGSIQKTPQIQVYSRHPPENGKPNILNCYVT
QFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFYILAHTEFTPTETDTYACR
VKHDSMAEPKTVYWDRDMEQKLISEEDLHMQLTTICEQIPSPITLESTPYSLS
5 TTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPIINTQYVFKDNSSTI
EGRYPYDVPDYA

Nucleic Acid Sequence 3: dEP.4 (SEQ ID NO:36)

10 GAATTCTACTTCATACATTTTCAATTAAGATGCAGTTACTTCGCTGTTTTTCA
ATATTTTCTGTTATTGCTTCAGTTTTAGCAGCTAGCTTGGATAAAAGAGAACA
ATACAAATTCTACTCAGTTCTTAAGGGTGGACCAGGTGGAGGTTTCAGGAGGTG
GAGGCCACACTCGCTGAGGTATTTCTGTCACCGCCGTGTCCCGGCCCGGCCTC
15 GGGGAGCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCG
CTTCAACAGCGACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGG
AGCAGGAGGGGCCCGAGTATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAAT
GAGCAGAGTTTCCGAGTGGACCTGAGGACCCTGCTCGGCTACTACAACCAGAG
CAAGGGCGGCTCTCACACTATTCAGGTGATCTCTGGCTGTGAAGTGGGGTCCG
20 ACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCTACGACGGCTGCGATTAC
ATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGACATGGCGGCGCT
GATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAGGGCCT
ACCTGGAGGGCACGTGCGTGGAGAGGCTCCGCAGATACCTGAAGAACGGGAAC
GCGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACAGCAG
25 ACCTGAAGATAAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCTG
ACATCACCTGACCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACATGGAG
CTTGTGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGT
GGTGGTGCTTCTTGGGAAGGAGCAGTATTACACATGCCATGTGTACCATCAGG
GGCTGCCTGAGCCCCTCACCTGAGATGGGAGGGTGAATAGGTTTCAGGTGGC
30 GGTGGATCAGGAGGCGGAGGTTCAATCCAGAAAACCCCTCAAATTCAAGTATA
CTCACGCCACCCACCGGAGAATGGGAAGCCG

Amino Acid Sequence 3: dEP.4 (SEQ ID NO:37)

35 ILLHTFSIKMQLLRCSIFSIVIASVLAASLDKREQYKFYSVLKGGPGGGSGGG
GPHSLRYFVTAVSRPGLGEPRYMEVGIVDDTEFVRFNSDAENPRYEPRARWME
QEGPEYWERETQKAKGNEQSFVRDLRTLGLYYNQSKGGSHTIQVISGCEVGS
GRLLRGYQQYAYDGCYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAY
40 LEGTCVERLRRYLKNGNATLLRTDSPKAHVTHHSRPEDKVTLCWALGFYPAD

ITLTWQLNGEELIQDMELVETRPAGDGTFOKWASVVVPLGKEQYYTCHVYHQG
LPEPLTLRWEGGIGSGGGGSGGGGSIQKTPQIQVYSRHPPENGKPNILNCYVT
QFHPPHIEIQMLKNGKKIPKVEMSDMSFSKDWSFNILAHTFTPTETDTYACR
VKHDSMAEPKTVYWDRDMEQRLISEEDLHMQELTTICEQIPSPITLESTPYSLS
5 TTTILANGKAMQGVFEYYKSVTFVSNCGSHPSTTSKGSPIINTQYVFKDNSSTI
EGRYPYDVPDYA

References

- Altschul, S.F. et al. (1997) *Nucl. Acids Res.* 25: 3389-3402.
- Boder, E. T., and Wittrup, K. D. (1997) *Nat. Biotech.* 15, 553-557.
- Bolin, D.R. et al. (2000) *J. Med. Chem.* 43(11), 2135-2148.
- Bouvier, M., and Wiley, D. C. (1994) *Science* 265(5170), 398-402.
- Brusic, V. et al. (1998) *Bioinformatics* 14(2), 121-130.
- Carrasco-Marin, E. et al. (1996) *J. Immunol.* 156(2), 450-458.
- Castano, A.R. et al. (1995) *Science* 269(5221), 223-226.
- Cho, B.K. et al. (1998) *J Immunol. Methods* 220(1-2), 179-188.
- Crawford, F. et al. (1998) *Immunity* 8(6), 675-682.
- Cresswell, P. (1994) *Annu. Rev. Immunol.* 12, 259-293.
- Davenport, M. P. et al. (1996) *Immunology* 88(4), 482-486.
- Davis, G. T. et al. (1991) *Biotechnology* 9(2), 165-169.
- Engelhard, V. H. (1994) *Curr. Op. Immunol.* 6, 13-23.
- Falcioni, F. et al. (1999) *Nat. Biotechnol.* 17(6), 562-567.
- Falk, K. et al. (1991) *Nature* 351(6324), 290-296.
- Fremont, D. H. et al. (1996) *Science* 272(5264), 1001-1004.
- Geitz, R. D. et al. (1995) *Yeast* 11, 355-360.
- Goldstein, J. S. et al. (1998) *J. Immunol.* 160(7), 3180-3187.
- Gregori, S. et al. (2000) *Int. Immunol.* 12(4), 493-503.
- Hammer, J. et al. (1992) *J. Exp. Med.* 176(4), 1007-1013.
- Hammer, J. et al (1993) *Cell* 74(1), 197-203.
- Harrison, L. C. et al. (1997) *J. Exp. Med.* 185(6), 1013-1021.
- Howard, M. C. et al. (1999) *Immunol. Today* 20(4), 161-165.
- Ignatowicz, L. et al. (1995) *J. Immunol.* 154(8), 3852-3862.
- Ishioka, G. Y. et al. (1994) *J. Immunol.* 152(9), 4310-4319.
- Kieke et al. (1997) *Proc. Natl. Acad. Sci. USA* 96,5651-5656
- Kozono, H. et al. (1994) *Nature* 369, 151-154.
- Kranz, D. M. et al. (1984) *Proc. Natl. Acad. Sci. USA* 81, 7922-7926.
- Lamont, A. G. et al. (1990) *J. Immunol.* 144, 2493.
- Le Doussal, J. et al. (2000) *J. Immunol. Methods* 241(1-2), 147-58.

- Lepley, D. M. et al. (1997) *Transplantation* 63(5), 765-774.
- Madden, D. R. (1995) *Annu. Rev. Immunol.* 13, 587-622.
- Mescher, M. F. et al. (1983) *Methods Enzymol.* 92, 86-109.
- Milik, M. et al. (1998) *Nat. Biotechnol.* 16(8), 753-756.
- Mottez, E. et al. (1995) *J. Exp. Med.* 181(2), 493-502.
- Onda, T. et al. (1995) *Mol. Immunol.* 32(17-18), 1387-1397.
- Rammensee, H. G. et al. (1995) *Immunogenetics* 41(4), 178-228.
- Raymond, C. K. et al. (1999) *Biotechniques* 26(1), 134-138, 140-141.
- Reay, P. A. et al. (1992) *EMBO J.* 11(8), 2829-2839.
- Ribaudo, R. K., and Margulies, D. H. (1995) *J. Immunol.* 155, 3481-3493.
- Ridgway, W. M. et al. (1999) *Science* 284(5415), 749-751.
- Rothbard, J. B. (1991) *Annual Review of Immunology* 9, 527-565.
- Rudensky, A. et al. (1992) *Nature* 359(6394), 429-431.
- Sakita, I. Et al. (1996) *J. Immunol. Methods* 192(1-2), 105-115.
- Schmitt, L. et al. (1999) *J. Mol. Biol.* 286(1), 207-218.
- Scott, C. A. et al. (1998) [published erratum appears in *Immunity* 1998 Apr;8(4):531] *Immunity* 8(3), 319-329.
- Sette, A. et al. (1994) *Annual Review of Immunology* 12, 413-431.
- Shields, M. J. et al. (1998) *J. Immunol.* 160(5), 2297-2307.
- Shields, M. J. et al. (1999) *Mol. Immunol.* 36(9), 561-573.
- Shirai, M. et al. (1997) *J. Immunol.* 158(7), 3181-3188.
- Shusta, B. V. et al. (1999) *J. Mol. Biol.*, 292, 949-956.
- Smith, J. D. et al. (1995) *Mol. Immunol.* 32(7), 531-540.
- Stern, L. et al. (1994) *Nature* 368, 215-221.
- Stern, L. J., and Wiley, D. C. (1992) *Cell* 68(3), 465-477.
- Udaka, K. et al. (1996) *J. Immunol.* 157, 670-678.
- Uger, R. A. et al. (1999) *J. Immunol.* 162(10), 6024-6028.
- Van der Burg, S. H. et al. (1996) *J. Immunol.* 156, 3308-3314.
- Wucherpennig, K. W. et al. (1995) *Proc. Natl. Acad. Sci. USA* 92(25), 11935-11939.
- Zhu, X. et al. (1997) *Eur. J. Immunol.* 27(8), 1933-1941.

WHAT IS CLAIMED IS:

1. A mutagenized combinatorial library of Major Histocompatibility Complex (MHC) Class I chimeric proteins displayed on the surfaces of recombinant yeast cells, wherein the mutagenized combinatorial library comprises at least one member MHC Class I chimeric protein which is improved in conformational stability or in specific target binding as compared with a comparison MHC Class I chimeric protein which has not been mutagenized.
2. The mutagenized combinatorial library of claim 1 wherein the MHC Class I chimeric protein comprises a portion mediating binding to the surfaces of the recombinant yeast cells and a portion which comprises a specific target binding region of a MHC Class I protein.
3. The mutagenized combinatorial library of claim 2 wherein the portion mediated binding to the surfaces of the recombinant yeast cells is a mating adhesion receptor portion.
4. The mutagenized combinatorial library of claim 3 wherein the mating adhesion receptor portion is an AGA2 portion.
5. The mutagenized combinatorial library of any of claims 2 to 4 wherein the chimeric protein further comprises a portion characterized by an amino acid sequence of a peptide which binds to the binding region of the MHC Class I chimeric protein.
6. The mutagenized combinatorial library of any of claims 2 to 5 wherein the chimeric protein further comprises a portion derived from a *c-myc* protein and which mediates binding to a *c-myc* specific antibody.
7. The mutagenized combinatorial library of any of claims 2 to 6 wherein the binding region of the MHC Class I chimeric protein specifically binds a specific target selected from the group consisting of a neoplastic cell, a virus-infected cell, a fungus-infected cell, a parasite-infected cell and a bacterium-infected cell.

8. The mutagenized combinatorial library of claim 8 wherein the peptide binding region specifically binds a peptide having the amino acid sequence given in SEQ ID NO:19, SEQ ID NO:22 or SEQ ID NO:24.
9. The mutagenized combinatorial library of claim 8 wherein said chimeric protein comprises an amino acid sequence as given in SEQ ID NO:17.
10. An isolated mutant MHC Class I chimeric protein, wherein said protein comprises a portion mediating binding to the surfaces of the recombinant yeast cells and a portion which comprises a peptide binding region of a MHC Class I protein and wherein said chimeric protein is improved in stability as compared with an MHC Class I chimeric protein which is not a mutant chimeric protein.
11. The isolated mutant MHC Class I chimeric protein of claim 10 wherein the chimeric protein further comprises a portion comprising an amino acid sequence of a peptide which binds to the peptide binding region of the MHC Class I protein.
12. The isolated mutant MHC Class I chimeric protein of claim 10 wherein a peptide which binds to the peptide binding region of the MHC Class I protein is associated with a neoplastic or infectious disease.
13. The isolated mutant MHC Class I chimeric protein of claim 10 wherein the peptide binding region specifically binds a peptide having the amino acid sequence given in SEQ ID NO:19, SEQ ID NO:22 or SEQ ID NO:24.
14. The isolated mutant MHC Class I chimeric protein of claim 11 wherein said chimeric protein further comprises a detectable label.
15. The isolated mutant MHC Class I chimeric protein of claim 15 wherein the detectable label is a fluorescent moiety, a chromophore, a radionuclide, a chemiluminescent agent, a magnetic particle, an enzyme, a cofactor, a substrate or a toxin.
16. A method for detection of a lymphocyte having a T cell receptor protein in a biological sample, said method comprising the steps of contacting the sample with an isolated

- mutant chimeric protein of claim 14, wherein said chimeric protein is complexed to the peptide or wherein the chimeric protein and peptide are covalently bound, wherein said chimeric protein comprises a binding region which specifically binds said T cell receptor protein under conditions which allow the binding of the T cell receptor protein to the chimeric protein, and detecting the chimeric protein bound to the T cell receptor protein.
17. The method of claim 16 wherein the T lymphocyte is specific for a neoplastic cell, a tumor cell, a virus-infected cell, a protozoan-infected cell, a bacterium-infected cell or a fungus-infected cell.
 18. The method of claim 16 or 17 wherein the biological sample is cells, a tissue sample, biopsy material or bodily fluids.
 19. A method for activating or enhancing an immune response to an abnormal cell selected from the group consisting of a neoplastic cell, a tumor cell, a virus-infected cell, a parasite-infected cell, a fungus infected cell or a protozoan infected cell in a human or animal, said method comprising the step of administering to the patient a therapeutically effective amount of an isolated mutant MHC Class I chimeric protein or a mutant MHC Class I chimeric protein/peptide complex which is improved in conformational stability or improved in binding to T lymphocyte as compared with the MHC Class I chimeric protein which is not mutant, whereby the immune response in the human or animal is activated or enhanced.
 20. The method of claim 19 wherein the administering is by intravenous, intramuscular, intradermal, subcutaneous or intraperitoneal administration.
 21. The method of claim 20 wherein said isolated mutant protein has a portion comprising an amino acid sequence as given in SEQ ID NO:17.
 22. The method of claim 21 wherein said mutant protein binds a peptide comprising an amino acid sequence as given in SEQ ID NO:19, SEQ ID NO:22 or SEQ ID NO:24.

23. A combinatorial library of peptides anchored to the surface of yeast cells, each cell displaying a peptide of a unique sequence anchored to its surface, wherein the peptide is anchored to the surface of the yeast cell by a mating factor sequence.
24. The combinatorial library of claim 23 wherein the mating factor sequence is an AGA2 sequence.
25. A method for identifying a peptide which binds specifically to an MHC protein comprising the step of contacting a detectable MHC protein with the combinatorial library of claim 24 or 25 under conditions which allow binding of the protein and the peptide, and detecting peptide bound to the MHC protein.




FIG. 1

2/20

- MHC protein fused to mating adhesion receptor, Aga-2
- epitope tags for normalization (HA, c-myc)




FIG. 2

3/20




FIG. 3




FIG. 4

5/20




FIG. 5

6/20




Fig 6A 2C T cells, no yeast
Mean Fluorescent Units for FITC-anti-CD69 = 2.26




Fig 6B 2C T cells, yeast with K^b only (10⁶ cells)
Mean Fluorescent Units for FITC-anti-CD69 = 5.79




Fig 6C 2C T cells, yeast with anti-TCR scFv (10⁶ cells)
Mean Fluorescent Units for FITC-anti-CD69 = 12.8





Fig 6D 2C T cells, yeast with SIYR/K^b (10⁶ cells)
Mean Fluorescent Units for FITC-anti-CD69 = 16.9

7/20



Yeast Cells ($\times 10^5$)

FIG. 7




FIG. 8

9/20




FIG. 9

10/20






FIG. 10

11/20



SIYR/K^b second sort with anti-K^b (antibody B.8.24.3)
 sorted top 0.25%
 MFU of population = 31.8




SIYR/K^b third sort with anti-K^b (antibody B.8.24.3)
 sorted top 0.1%
 MFU of population = 307

* dEV8/K^b library profiles similar to SIYR/K^b

FIG. 11

12/20



dEV8/Kb clone from error-prone PCR library (dEP)

FIG. 12

13/20



FIG. 13

• dEP.1 (same as dEP.2): 3 mutations

K^b W167R TGG(Trp) --> AGG(Arg)

β2m Y63N TAT(Tyr) --> AAT(Asn)

c-myc K3R AAG(Lys) --> AGG(Arg)

• dEP.3 - 1 mutation

K^b W167R TGG(Trp) --> CGG(Arg)

• dEP.4 - 4 mutations

all 3 of the above

K^b D37N GAC (Asp) --> AAC (Asn)

14/20

Construction of a directed, mutagenic peptide library in dEV8/K^b

- Sequence of dEV8: EQYKFYSV; from crystal structure:
 - E = P1 buried in the first pocket
 - Q = P2 directed down into the pocket
 - Y = P3 2° anchor residue, bulky
 - K = P3 1° TCR contact, directed out of pocket
 - F = P4 aromatic, into pocket, 1°MHC anchor
 - Y = P6 big, aromatic, TCR contact,
 - S = P7 small due to little space
 - V = P8 1° anchor, into the pocket
- To select mutations that stabilize dEV8 binding to K^b, produce library in positions that point into K^b:

dEV8 degenerate library at P1-P3: NN^bNKFYSV
- Library constructed by PCR and cloning into wt dEV8/K^b plasmid
- Sequenced 4 clones: all contained different nucleotides at P1-P3

FIG. 14

15/20




FIG. 15




FIG. 16

17/20




FIG. 17

Yeast display of peptides that bind to MHC class I K^b

Known K^b peptides (SIYR, dEV8, OVA) have anchor residues at peptide position 5 and position 8

P5 anchor residue = aromatic amino acid

P8 anchor residue = hydrophobic amino acid

	P5		P8
	↓		↓
S	I	Y	R
E	Q	Y	K
S	I	I	N
H	Y	S	P

	Y	G	L	-	SIYR
	Y	S	V	-	dEV8
	E	K	L	-	OVA
	Q	L	A	-	K ^b binding peptide

isolated by yeast display

FIG. 18

19/20




FIG. 19

20/20




FIG. 20

SEQUENCE LISTING

<110> Board of Trustees of the University of Illinois

<120> Mutated Class I Major Histocompatibility proteins and Complexes

<130> 100-00WO

<140> Not assigned

<141> 2001-12-10

<150> 60/254,495

<151> 2000-12-08

<160> 37

<170> PatentIn Ver. 2.0

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 1

Ser Ile Tyr Arg Tyr Tyr Gly Leu

1 5

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 2

Ser Ile Ile Asn Phe Glu Lys Leu

1 5

<210> 3

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic nucleotide primer

<220>

<221> misc_feature

<222> (1)..(63)

<223> N is A, T, G or C.

<400> 3

atattttctg ttattgcttc agtttttagca gctagcttgg ataaaagann snnsnnsaaa 60
ttc 63

<210> 4

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 4

Gln Leu Ser Pro Phe Pro Phe Asp Leu
1 5

<210> 5

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 5

Glu Gln Tyr Lys Phe Tyr Ser Val
1 5

<210> 6

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 6

Asn Asn Asn Lys Phe Tyr Ser Val
1 5

<210> 7

<211> 79

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 7

caatggctag cgggtggactt aagggtggac cagggtggagg ttcaggagggt ggaggcccac 60
actcgctgag gtatttcgt 79

<210> 8

<211> 72

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 8

tgaacctcg cctcctgac caccgccacc tgaacctatt ccaccctccc atctcagggt 60
gaggggctca gg 72

<210> 9

<211> 73

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 9

ggtggaatag gttcagggtgg cgggtggatca ggaggcggag gttcaatcca gaaaaccct 60
caaattcaag tat 73

<210> 10

<211> 71

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 10

gttcctcga gctattacaa gtcttcttca gaaataagct tttgttccat gtctcgatcc 60
cagtagacgg t 71

<210> 11

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 11

tctcaagaat tctacttcat acatttt

27

<210> 12
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 12
gtatctgcta gctgctaaaa ctgaagc 27

<210> 13
<211> 72
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 13
atactagcta gcttggataa aaggtctatt tatagatatt atggtttgct taagggtgga 60
ccaggtggag gt 72

<210> 14
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 14
caatccagat ctttactaat gcaagtcttc ttcagaaata ag 42

<210> 15
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 15
ggatatcata tgcaggaact gacaactata 30

<210> 16
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 16
atttgagat ctcgagttac taagcgtagt ctggaacgct gta 43

<210> 17
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 17
ctagcttgga taaaaggagc atcatcaatt ttgaaaagct tc 42

<210> 18
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 18
ttaagaagct tttcaaaatt gatgatgctc cttttatcca ag 42

<210> 19
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 19
ctagcttgga taaaaggga caatacaaat tctactcagt tc 42

<210> 20
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
nucleotide primer

<400> 20
ttaagaactg agtagaattt gtattgttcc cttttatcca ag 42

<210> 21
<211> 1632
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic nucleotide

<400> 21

```

atgcagttac ttcgctgttt ttcaatatTT tctgttattg cttcagtttt agcacaggaa 60
ctgacaacta tatgcgagca aatccccctca ccaacttttag aatcgacgcc gtactctttg 120
tcaacgacta ctatttttggc caacgggaag gcaatgcaag gagtttttga atattacaaa 180
tcagtaacgt ttgtcagtaa ttgcggttct caccctcaa caactagcaa aggcagcccc 240
ataaacacac agtatgtttt taaggacaat agctcgacga ttgaaggtag ataccatac 300
gacgttccag actacgctct gcaggctagt ggtggtggtg gttctggtg tgggtggttct 360
ggtggtggtg gttctgctag cgggtggactt aagggtggac cagggtggagg ttcaggaggt 420
ggaggcccac actcgtgag gtatttcgtc accgctgtt cccggcccg cctcggggag 480
ccccgtaca tggaaagtcg ctacgtggac gacacggagt tcgtgcgctt cgacagcgac 540
gcggagaatc cgagatatga gccgcggcg cgggtggatg agcaggagg gcccagtat 600
tgggagcggg agacacagaa agccaaggc aatgagcaga gtttccgagt ggacctgagg 660
accctgctcg gctactacaa ccagagcaag ggcggctctc acactattca ggtgatctct 720
ggctgtgaag tggggtccga cgggcgactc ctccgcgggt accagcagta cgcctacgac 780
ggctgcgatt acatgcctt gaacgaagac ctgaaaacgt ggacggcggc ggacatggcg 840
gcgtgatca ccaaacacaa gtgggagcag gctggtgaag cagagagact cagggcctac 900
ctggagggca ctgctgtgga gtggctccgc agatacctga agaacgggaa cgcgacgctg 960
ctgcgcacag attccccaaa ggcccatgtg acccatcaca gcagacctga agataaagtc 1020
accctgaggt gctgggcccct gggcttctac cctgctgaca tcacctgac ctggcagttg 1080
aatggggagg agctgatcca ggacatggag cttgtggaga ccaggcctgc aggggatgga 1140
accttcaga agtgggcatc tgtggtggtg cctcttgga aggagcagta ttacacatgc 1200
catgtgtacc atcaggggct gcctgagccc ctcacctga gatgggaggg tggaaatagg 1260
tcagggtggc gtggatcagg aggcggagg tcaatccaga aaaccctca aattcaagta 1320
tactcacgcc acccaccgga gaatgggaag ccgaacatac tgaactgcta cgtaacacag 1380
ttccaccgc ctcacattga aatccaaatg ctgaagaacg ggaaaaaat tcctaaagta 1440
gagatgtcag atatgtcctt cagcaaggac tggctcttct atatcctggc tcacactgaa 1500
ttcaccacca ctgagactga tacatacgcc tgcagagtta agcatgacag tatggccgag 1560
cccaagaccg tctactggga tcgagacatg gaacaaaagc ttatttctga agaagacttg 1620
taatagctcg ag 1632

```

<210> 22

<211> 540

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 22

```

Met Gln Leu Leu Arg Cys Phe Ser Ile Phe Ser Val Ile Ala Ser Val
  1                      5                      10                     15

```

```

Leu Ala Gln Glu Leu Thr Thr Ile Cys Glu Gln Ile Pro Ser Pro Thr
                20                      25                     30

```

```

Leu Glu Ser Thr Pro Tyr Ser Leu Ser Thr Thr Thr Ile Leu Ala Asn
                35                      40                     45

```

```

Gly Lys Ala Met Gln Gly Val Phe Glu Tyr Tyr Lys Ser Val Thr Phe
  50                      55                     60

```

```

Val Ser Asn Cys Gly Ser His Pro Ser Thr Thr Ser Lys Gly Ser Pro
  65                      70                     75                     80

```


Ile Asn Thr Gln Tyr Val Phe Lys Asp Asn Ser Ser Thr Ile Glu Gly
 85 90 95
 Arg Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Gln Ala Ser Gly Gly
 100 105 110
 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Ser Gly
 115 120 125
 Gly Leu Lys Gly Gly Pro Gly Gly Gly Ser Gly Gly Gly Gly Pro His
 130 135 140
 Ser Leu Arg Tyr Phe Val Thr Ala Val Ser Arg Pro Gly Leu Gly Glu
 145 150 155 160
 Pro Arg Tyr Met Glu Val Gly Tyr Val Asp Asp Thr Glu Phe Val Arg
 165 170 175
 Phe Asp Ser Asp Ala Glu Asn Pro Arg Tyr Glu Pro Arg Ala Arg Trp
 180 185 190
 Met Glu Gln Glu Gly Pro Glu Tyr Trp Glu Arg Glu Thr Gln Lys Ala
 195 200 205
 Lys Gly Asn Glu Gln Ser Phe Arg Val Asp Leu Arg Thr Leu Leu Gly
 210 215 220
 Tyr Tyr Asn Gln Ser Lys Gly Gly Ser His Thr Ile Gln Val Ile Ser
 225 230 235 240
 Gly Cys Glu Val Gly Ser Asp Gly Arg Leu Leu Arg Gly Tyr Gln Gln
 245 250 255
 Tyr Ala Tyr Asp Gly Cys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Lys
 260 265 270
 Thr Trp Thr Ala Ala Asp Met Ala Ala Leu Ile Thr Lys His Lys Trp
 275 280 285
 Glu Gln Ala Gly Glu Ala Glu Arg Leu Arg Ala Tyr Leu Glu Gly Thr
 290 295 300
 Cys Val Glu Trp Leu Arg Arg Tyr Leu Lys Asn Gly Asn Ala Thr Leu
 305 310 315 320
 Leu Arg Thr Asp Ser Pro Lys Ala His Val Thr His His Ser Arg Pro
 325 330 335
 Glu Asp Lys Val Thr Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala
 340 345 350
 Asp Ile Thr Leu Thr Trp Gln Leu Asn Gly Glu Glu Leu Ile Gln Asp
 355 360 365
 Met Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys
 370 375 380

Trp Ala Ser Val Val Val Pro Leu Gly Lys Glu Gln Tyr Tyr Thr Cys
385 390 395 400

His Val Tyr His Gln Gly Leu Pro Glu Pro Leu Thr Leu Arg Trp Glu
405 410 415

Gly Gly Ile Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ile
420 425 430

Gln Lys Thr Pro Gln Ile Gln Val Tyr Ser Arg His Pro Pro Glu Asn
435 440 445

Gly Lys Pro Asn Ile Leu Asn Cys Tyr Val Thr Gln Phe His Pro Pro
450 455 460

His Ile Glu Ile Gln Met Leu Lys Asn Gly Lys Lys Ile Pro Lys Val
465 470 475 480

Glu Met Ser Asp Met Ser Phe Ser Lys Asp Trp Ser Phe Tyr Ile Leu
485 490 495

Ala His Thr Glu Phe Thr Pro Thr Glu Thr Asp Thr Tyr Ala Cys Arg
500 505 510

Val Lys His Asp Ser Met Ala Glu Pro Lys Thr Val Tyr Trp Asp Arg
515 520 525

Asp Met Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
530 535 540

<210> 23

<211> 1640

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
nucleotide

<400> 23

```
gaattctact tcatacattt tcaattaaga tgcagttact tcgctgtttt tcaatatttt 60
ctgttattgc ttcagtttta gcagctagct tggataaaag atctatttat agatattatg 120
gtttgcttaa ggggtggacca ggtggagggt caggaggtgg aggcccacac tcgctgaggt 180
atttcgtcac cgccgtgtcc cggcccggcc tcggggagcc ccggtacatg gaagtcggct 240
acgtggacga cacggagttc gtgcgcttcg acagcgacgc ggagaatccg agatatgagc 300
cgcgggcgcg gtggatggag caggaggggc ccgagtattg ggagcgggag acacagaaaag 360
ccaagggcaa tgagcagagt ttccgagtgg acctgaggac cctgctcggc tactacaacc 420
agagcaaggg cggctctcac actattcagg tgatctctgg ctgtgaagtg ggggtccgacg 480
ggcgactcct ccgcgggtac cagcagtacg cctacgacgg ctgcgattac atcgccctga 540
acgaagacct gaaaacgtgg acggcgggcg acatggcggc gctgatcacc aaacacaagt 600
gggagcaggc tggatgaagc gagagactca gggcctacct ggagggcacg tgcgtggagt 660
ggctccgcag atacctgaag aacgggaacg cgacgtgct gcgcacagat tccccaaagg 720
cccattgtac ccattcacgc agacctgaag ataaagtcac cctgaggtgc tgggcccctg 780
gcttctaccc tgctgacatc accctgacct ggcagttgaa tggggaggag ctgatccagg 840
acatggagct tgtggagacc aggcctgcag gggatggaac cttccagaag tgggcatctg 900
tggtggtgcc tcttgggaag gagcagtatt acacatgcca tgtgtaccat caggggctgc 960
```

```

ctgagcccct caccctgaga tgggagggtg gaatagggtc aggtggcggt ggatcaggag 1020
gcggagggtc aatccagaaa acccctcaaa ttcaagtata ctcacgccac ccaccggaga 1080
atgggaagcc gaacatactg aactgctacg taacacagtt ccaccgcct cacattgaaa 1140
tccaaatgct gaagaacggg aaaaaaattc ctaaagtaga gatgtcagat atgtccttca 1200
gcaaggactg gtctttctat atcctggctc acactgaatt cacccccact gagactgata 1260
catacgctg cagagttaag catgacagta tggccgagcc caagaccgtc tactgggatc 1320
gagacatgga acaaaagctt atttctgaag aagacttgca tatgcaggaa ctgacaacta 1380
tatgcgagca aatccctca ccaactttag aatcgacgcc gtactctttg tcaacgacta 1440
ctattttggc caacgggaag gcaatgcaag gagtttttga atattacaaa tcagtaacgt 1500
ttgtcagtaa ttgcggttct caccctcaa caactagcaa aggcagcccc ataaacacac 1560
agtatgtttt taaggacaat agctcgacga ttgaaggtag ataccatac gacgttccag 1620
actacgctta gtaactcgag                                     1640

```

<210> 24

<211> 542

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 24

```

Ile Leu Leu His Thr Phe Ser Ile Lys Met Gln Leu Leu Arg Cys Phe
  1                   5                   10                   15

```

```

Ser Ile Phe Ser Val Ile Ala Ser Val Leu Ala Ala Ser Leu Asp Lys
      20                   25                   30

```

```

Arg Ser Ile Tyr Arg Tyr Tyr Gly Leu Leu Lys Gly Gly Pro Gly Gly
    35                   40                   45

```

```

Gly Ser Gly Gly Gly Gly Pro His Ser Leu Arg Tyr Phe Val Thr Ala
    50                   55                   60

```

```

Val Ser Arg Pro Gly Leu Gly Glu Pro Arg Tyr Met Glu Val Gly Tyr
    65                   70                   75                   80

```

```

Val Asp Asp Thr Glu Phe Val Arg Phe Asp Ser Asp Ala Glu Asn Pro
      85                   90                   95

```

```

Arg Tyr Glu Pro Arg Ala Arg Trp Met Glu Gln Glu Gly Pro Glu Tyr
    100                   105                   110

```

```

Trp Glu Arg Glu Thr Gln Lys Ala Lys Gly Asn Glu Gln Ser Phe Arg
    115                   120                   125

```

```

Val Asp Leu Arg Thr Leu Leu Gly Tyr Tyr Asn Gln Ser Lys Gly Gly
    130                   135                   140

```

```

Ser His Thr Ile Gln Val Ile Ser Gly Cys Glu Val Gly Ser Asp Gly
    145                   150                   155                   160

```

```

Arg Leu Leu Arg Gly Tyr Gln Gln Tyr Ala Tyr Asp Gly Cys Asp Tyr
    165                   170                   175

```

Ile Ala Leu Asn Glu Asp Leu Lys Thr Trp Thr Ala Ala Asp Met Ala
 180 185 190
 Ala Leu Ile Thr Lys His Lys Trp Glu Gln Ala Gly Glu Ala Glu Arg
 195 200 205
 Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr
 210 215 220
 Leu Lys Asn Gly Asn Ala Thr Leu Leu Arg Thr Asp Ser Pro Lys Ala
 225 230 235 240
 His Val Thr His His Ser Arg Pro Glu Asp Lys Val Thr Leu Arg Cys
 245 250 255
 Trp Ala Leu Gly Phe Tyr Pro Ala Asp Ile Thr Leu Thr Trp Gln Leu
 260 265 270
 Asn Gly Glu Glu Leu Ile Gln Asp Met Glu Leu Val Glu Thr Arg Pro
 275 280 285
 Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ser Val Val Val Pro Leu
 290 295 300
 Gly Lys Glu Gln Tyr Tyr Thr Cys His Val Tyr His Gln Gly Leu Pro
 305 310 315 320
 Glu Pro Leu Thr Leu Arg Trp Glu Gly Gly Ile Gly Ser Gly Gly Gly
 325 330 335
 Gly Ser Gly Gly Gly Gly Ser Ile Gln Lys Thr Pro Gln Ile Gln Val
 340 345 350
 Tyr Ser Arg His Pro Pro Glu Asn Gly Lys Pro Asn Ile Leu Asn Cys
 355 360 365
 Tyr Val Thr Gln Phe His Pro Pro His Ile Glu Ile Gln Met Leu Lys
 370 375 380
 Asn Gly Lys Lys Ile Pro Lys Val Glu Met Ser Asp Met Ser Phe Ser
 385 390 395 400
 Lys Asp Trp Ser Phe Tyr Ile Leu Ala His Thr Glu Phe Thr Pro Thr
 405 410 415
 Glu Thr Asp Thr Tyr Ala Cys Arg Val Lys His Asp Ser Met Ala Glu
 420 425 430
 Pro Lys Thr Val Tyr Trp Asp Arg Asp Met Glu Gln Lys Leu Ile Ser
 435 440 445
 Glu Glu Asp Leu His Met Gln Glu Leu Thr Thr Ile Cys Glu Gln Ile
 450 455 460
 Pro Ser Pro Thr Leu Glu Ser Thr Pro Tyr Ser Leu Ser Thr Thr Thr
 465 470 475 480

Ile Leu Ala Asn Gly Lys Ala Met Gln Gly Val Phe Glu Tyr Tyr Lys
 485 490 495

Ser Val Thr Phe Val Ser Asn Cys Gly Ser His Pro Ser Thr Thr Ser
 500 505 510

Lys Gly Ser Pro Ile Asn Thr Gln Tyr Val Phe Lys Asp Asn Ser Ser
 515 520 525

Thr Ile Glu Gly Arg Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 530 535 540

<210> 25

<211> 1640

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 nucleotide

<400> 25

```

gaattctact tcatacattt tcaattaaga tgcagttact tcgctgtttt tcaatatttt 60
ctgttattgc ttcagtttta gcagctagct tggataaaag agaacaatac aaattctact 120
cagttcttaa gggtagacca ggtggagggt caggagggtg aggcccacac tcgctgaggt 180
atttcgtcac cgccgtgtcc cggcccgcc tcggggagcc ccggtacatg gaagtcggct 240
acgtggacga cacggagttc gtgcgcttcg acagcgacgc ggagaatccg agatatgagc 300
cgcgggcgcg gtggatggag caggaggggc ccgagtattg ggagcgggag acacagaaag 360
ccaagggcaa tgagcagagt ttccgagtgg acctgaggac cctgctcggc tactacaacc 420
agagcaaggg oggctctcac actattcagg tgatctctgg ctgtgaagtg gggtcggacg 480
ggcgactcct ccgcggttac cagcagtagc cctacgacgg ctgcgattac atcgccctga 540
acgaagacct gaaaacgtgg acggcgggcg acatggcggc gctgatcacc aaacacaagt 600
gggagcaggc tgggtgaagca gagagactca gggcctacct ggagggcacg tgcgtggagt 660
ggctccgcag atacctgaag aacgggaacg cgacgctgct gcgcacagat tcccaaagg 720
cccatgtgac ccatcacagc agacctgaag ataaagtcac cctgaggtgc tgggccctgg 780
gcttctaccc tgttgacatc accctgacct ggcaagtgaa tggggaggag ctgatccagg 840
acatggagct tgtggagacc aggcctgcag gggatggaac cttccagaag tgggcatctg 900
tggttggtgc tcttggaag gagcagtagt acacatgcca tgtgtaccat caggggctgc 960
ctgagccctt caccctgaga tgggaggggt gaatagggtt aggtggcggt ggatcaggag 1020
gcgaggggtt aatccagaaa acccctcaaa ttcaagtata ctacgccac ccaccggaga 1080
atgggaagcc gaacatactg aactgctacg taacacagtt ccaccgcct cacattgaaa 1140
tccaaatgct gaagaacggg aaaaaaatc ctaaagtaga gatgtcagat atgtccttca 1200
gcaaggactg gtctttctat atcctggctc aactgaatt cacccccact gagactgata 1260
catagcctg cagagttaag catgacagta tggccgagcc caagaccgtc tactgggatc 1320
gagacatgga acaaaagctt atttctgaag aagacttgca tatgcaggaa ctgacaacta 1380
tatgcgagca aatccctca ccaactttag aatcgacgcc gtactctttg tcaacgacta 1440
ctattttggc caacgggaag gcaatgcaag gagtttttga atattacaaa ttagtaacgt 1500
ttgtcagtaa ttgcggttct caccctcaa caactagcaa aggcagcccc ataaacacac 1560
agtatgtttt taaggacaat agctcgacga ttgaaggtag ataccatac gacgttccag 1620
actacgctta gtaactcgag                                     1640

```

<210> 26

<211> 542

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 26

Ile Leu Leu His Thr Phe Ser Ile Lys Met Gln Leu Leu Arg Cys Phe
 1 5 10 15

Ser Ile Phe Ser Val Ile Ala Ser Val Leu Ala Ala Ser Leu Asp Lys
 20 25 30

Arg Glu Gln Tyr Lys Phe Tyr Ser Val Leu Lys Gly Gly Pro Gly Gly
 35 40 45

Gly Ser Gly Gly Gly Gly Pro His Ser Leu Arg Tyr Phe Val Thr Ala
 50 55 60

Val Ser Arg Pro Gly Leu Gly Glu Pro Arg Tyr Met Glu Val Gly Tyr
 65 70 75 80

Val Asp Asp Thr Glu Phe Val Arg Phe Asp Ser Asp Ala Glu Asn Pro
 85 90 95

Arg Tyr Glu Pro Arg Ala Arg Trp Met Glu Gln Glu Gly Pro Glu Tyr
 100 105 110

Trp Glu Arg Glu Thr Gln Lys Ala Lys Gly Asn Glu Gln Ser Phe Arg
 115 120 125

Val Asp Leu Arg Thr Leu Leu Gly Tyr Tyr Asn Gln Ser Lys Gly Gly
 130 135 140

Ser His Thr Ile Gln Val Ile Ser Gly Cys Glu Val Gly Ser Asp Gly
 145 150 155 160

Arg Leu Leu Arg Gly Tyr Gln Gln Tyr Ala Tyr Asp Gly Cys Asp Tyr
 165 170 175

Ile Ala Leu Asn Glu Asp Leu Lys Thr Trp Thr Ala Ala Asp Met Ala
 180 185 190

Ala Leu Ile Thr Lys His Lys Trp Glu Gln Ala Gly Glu Ala Glu Arg
 195 200 205

Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr
 210 215 220

Leu Lys Asn Gly Asn Ala Thr Leu Leu Arg Thr Asp Ser Pro Lys Ala
 225 230 235 240

His Val Thr His His Ser Arg Pro Glu Asp Lys Val Thr Leu Arg Cys
 245 250 255

Trp Ala Leu Gly Phe Tyr Pro Ala Asp Ile Thr Leu Thr Trp Gln Leu
 260 265 270

Asn Gly Glu Glu Leu Ile Gln Asp Met Glu Leu Val Glu Thr Arg Pro
 275 280 285
 Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ser Val Val Val Pro Leu
 290 295 300
 Gly Lys Glu Gln Tyr Tyr Thr Cys His Val Tyr His Gln Gly Leu Pro
 305 310 315 320
 Glu Pro Leu Thr Leu Arg Trp Glu Gly Gly Ile Gly Ser Gly Gly Gly
 325 330 335
 Gly Ser Gly Gly Gly Gly Ser Ile Gln Lys Thr Pro Gln Ile Gln Val
 340 345 350
 Tyr Ser Arg His Pro Pro Glu Asn Gly Lys Pro Asn Ile Leu Asn Cys
 355 360 365
 Tyr Val Thr Gln Phe His Pro Pro His Ile Glu Ile Gln Met Leu Lys
 370 375 380
 Asn Gly Lys Lys Ile Pro Lys Val Glu Met Ser Asp Met Ser Phe Ser
 385 390 395 400
 Lys Asp Trp Ser Phe Tyr Ile Leu Ala His Thr Glu Phe Thr Pro Thr
 405 410 415
 Glu Thr Asp Thr Tyr Ala Cys Arg Val Lys His Asp Ser Met Ala Glu
 420 425 430
 Pro Lys Thr Val Tyr Trp Asp Arg Asp Met Glu Gln Lys Leu Ile Ser
 435 440 445
 Glu Glu Asp Leu His Met Gln Glu Leu Thr Thr Ile Cys Glu Gln Ile
 450 455 460
 Pro Ser Pro Thr Leu Glu Ser Thr Pro Tyr Ser Leu Ser Thr Thr Thr
 465 470 475 480
 Ile Leu Ala Asn Gly Lys Ala Met Gln Gly Val Phe Glu Tyr Tyr Lys
 485 490 495
 Ser Val Thr Phe Val Ser Asn Cys Gly Ser His Pro Ser Thr Thr Ser
 500 505 510
 Lys Gly Ser Pro Ile Asn Thr Gln Tyr Val Phe Lys Asp Asn Ser Ser
 515 520 525
 Thr Ile Glu Gly Arg Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 530 535 540

<210> 27

<211> 1640

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
nucleotide

<400> 27

```

gaattctact tcatacattt tcaattaaga tgcagttact tcgctgtttt tcaatatttt 60
ctgttattgc ttcagtttta gcagctagct tggataaaag gagcatcatc aattttgaaa 120
agcttcttaa ggggtggacca ggtggagggt caggagggtg agggccacac tcgctgaggt 180
atttcgtcac cgcggtgtcc cggcccgccc tcggggagcc ccggtacatg gaagtcggct 240
acgtggacga cacggagttc gtgcgcttcg acagcgacgc ggagaatccg agatatgagc 300
cgcgggcgcg gtggatggag caggaggggc ccgagtattg ggagcgggag acacagaaag 360
ccaagggcaa tgagcagagt ttccgagtgg acctgaggac cctgctcggc tactacaacc 420
agagcaaggg cggctctcac actattcagg tgatctctgg ctgtgaagtg gggtcggacg 480
ggcgactcct ccgcgggtac cagcagtagc cctacgacgg ctgcgattac atcgccctga 540
acgaagacct gaaaacgtgg acggcggcgg acatggcggc gctgatcacc aaacacaagt 600
gggagcaggc tggatgaagc gagagactca gggcctacct ggagggcacg tgcgtggagt 660
ggctccgcag atacctgaag aacgggaacg cgacgctgct gcgcacagat tccccaaagg 720
cccattgtgac ccatcacagc agacctgaag ataaagtcac cctgaggtgc tgggccctgg 780
gcttttaccg tgctgacatc accctgacct ggagttgaa tggggaggag ctgatccagg 840
acatggagct tgtggagacc aggcctgcag gggatggaac cttccagaag tgggcatctg 900
tgggtggtgcc tcttgggaag gagcagtatt acacatgcc a tgtgtaccat caggggctgc 960
ctgagcccct caccctgaga tgggagggtg gaataggttc aggtggcggg ggatcaggag 1020
gcgagggttc aatccagaaa acccctcaa ttcaagtata ctcacgccac ccaccggaga 1080
atgggaagcc gaacatactg aactgctacg taacacagtt ccaccgcct cacattgaaa 1140
tccaaatgct gaagaacggg aaaaaaattc cttaaagtaga gatgtcagat atgtccttca 1200
gcaaggactg gtctttctat atctggctc acactgaatt caccctcact gagactgata 1260
catacgctg cagagtttaag catgacagta tggccgagcc caagaccgtc tactgggata 1320
gagacatgga acaaaagctt atttctgaag aagacttgca tatgcaggaa ctgacaacta 1380
tatgcgagca aatcccttca ccaactttag aatcgacgcc gtactctttg tcaacgacta 1440
ctattttggc caacgggaag gcaatgcaag gagtttttga atattacaaa tcagtaacgt 1500
ttgtcagtaa ttgcggttct caccctcaa caactagcaa aggcagcccc ataaacacac 1560
agtatgtttt taaggacaat agctcgacga ttgaaggtag ataccatac gacgttccag 1620
actacgctta gtaactcgag 1640

```

<210> 28

<211> 541

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 28

```

Ile Leu Leu His Thr Phe Ser Ile Lys Met Gln Leu Leu Arg Cys Phe
  1             5             10             15

Ser Ile Phe Ser Val Ile Ala Ser Val Leu Ala Ala Ser Leu Asp Lys
      20             25             30

Arg Ser Ile Ile Asn Phe Glu Lys Leu Leu Lys Gly Gly Pro Gly Gly
      35             40             45

Gly Ser Gly Gly Gly Gly Pro His Ser Leu Arg Tyr Phe Val Thr Ala
      50             55             60

```


Val Ser Arg Pro Gly Leu Gly Glu Pro Arg Tyr Met Glu Val Gly Tyr
 65 70 75 80
 Val Asp Asp Thr Glu Phe Val Arg Phe Asp Ser Asp Ala Glu Asn Pro
 85 90 95
 Arg Tyr Glu Pro Arg Ala Arg Trp Met Glu Gln Glu Gly Pro Glu Tyr
 100 105 110
 Trp Glu Arg Glu Thr Gln Lys Ala Lys Gly Asn Glu Gln Ser Phe Arg
 115 120 125
 Val Asp Leu Arg Thr Leu Leu Gly Tyr Tyr Asn Gln Ser Lys Gly Gly
 130 135 140
 Ser His Thr Ile Gln Val Ile Ser Gly Cys Glu Val Gly Ser Asp Gly
 145 150 155 160
 Arg Leu Leu Arg Gly Tyr Gln Gln Tyr Ala Tyr Asp Gly Cys Asp Tyr
 165 170 175
 Ile Ala Leu Asn Glu Asp Leu Lys Thr Trp Thr Ala Ala Asp Met Ala
 180 185 190
 Ala Leu Ile Thr Lys His Lys Trp Glu Gln Ala Gly Glu Ala Glu Arg
 195 200 205
 Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu Arg Arg Tyr
 210 215 220
 Leu Lys Asn Gly Asn Ala Thr Leu Leu Arg Thr Asp Ser Pro Lys Ala
 225 230 235 240
 His Val Thr His His Ser Arg Pro Glu Asp Lys Val Thr Leu Arg Cys
 245 250 255
 Trp Ala Leu Gly Phe Tyr Pro Ala Asp Ile Thr Leu Thr Trp Gln Leu
 260 265 270
 Asn Gly Glu Glu Leu Ile Gln Asp Met Glu Leu Val Glu Thr Arg Pro
 275 280 285
 Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ser Val Val Val Pro Leu
 290 295 300
 Gly Lys Glu Gln Tyr Tyr Thr Cys His Val Tyr His Gln Gly Leu Pro
 305 310 315 320
 Glu Pro Leu Thr Leu Arg Trp Glu Gly Gly Ile Gly Ser Gly Gly Gly
 325 330 335
 Gly Ser Gly Gly Gly Gly Ser Ile Gln Lys Thr Pro Gln Ile Gln Val
 340 345 350
 Tyr Ser Arg His Pro Pro Glu Asn Gly Lys Pro Asn Ile Leu Asn Cys
 355 360 365

Tyr Val Thr Gln Phe His Pro Pro His Ile Glu Ile Gln Met Leu Lys
 370 375 380
 Asn Gly Lys Lys Ile Pro Lys Val Glu Met Ser Asp Met Ser Phe Ser
 385 390 395 400
 Lys Asp Trp Ser Phe Tyr Ile Leu Ala His Thr Glu Phe Thr Pro Glu
 405 410 415
 Thr Asp Thr Tyr Ala Cys Arg Val Lys His Asp Ser Met Ala Glu Pro
 420 425 430
 Lys Thr Val Tyr Trp Asp Arg Asp Met Glu Gln Lys Leu Ile Ser Glu
 435 440 445
 Glu Asp Leu His Met Gln Glu Leu Thr Thr Ile Cys Glu Gln Ile Pro
 450 455 460
 Ser Pro Thr Leu Glu Ser Thr Pro Tyr Ser Leu Ser Thr Thr Thr Ile
 465 470 475 480
 Leu Ala Asn Gly Lys Ala Met Gln Gly Val Phe Glu Tyr Tyr Lys Ser
 485 490 495
 Val Thr Phe Val Ser Asn Cys Gly Ser His Pro Ser Thr Thr Ser Lys
 500 505 510
 Gly Ser Pro Ile Asn Thr Gln Tyr Val Phe Lys Asp Asn Ser Ser Thr
 515 520 525
 Ile Glu Gly Arg Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 530 535 540

<210> 29

<211> 1631

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic nucleotide

<400> 29

atgcagttac ttcgctgttt ttcaatattt tctgttattg cttcagtttt agcacaggaa 60
 ctgacaacta tatgcgagca aatcccctca ccaacttttag aatcgacgcc gtactctttg 120
 tcaacgacta ctattttggc caacgggaag gcaatgcaag gagtttttga atattacaaa 180
 tcagtaacgt ttgtcagtaa ttgcggttct caccctcaa caactagcaa aggcagcccc 240
 ataaacacac agtatgtttt taaggacaat agctcgacga ttgaaggtag ataccatac 300
 gacgttccag actacgctct gcaggctagt ggtggtggtg gttcggtggt ggtggttctg 360
 gtggtggtgg ttctgctagc ggtggactta aggggtggacc aggtggaggt tcaggaggtg 420
 gagggccaca ctcgatgcgg tatttcgaga ccgcggtgtc ccggcgcggc ctcggggagc 480
 ccggtacat ctctgtcggc tatgtgaacg acaaggagtt cgtgcgcttc gacagcgacg 540
 cggagaatcc gagatatgag ccgagggcgc cgtggatgga gcaggagggg ccggagtatt 600
 gggagcggat cagcgagatc gccaaaggcc aggagcagtg gttccgagtg aacctgagga 660
 ccctgctcgg ctactacaac cagagcgcgg gcggcactca cacactccag tggatgtacg 720
 gctgtgacgt ggggtcggac gggcgccctc tccgcgggta cgagcagttc gcctacgacg 780

```

gctgcgatta catcgccctg aacgaagacc tgaaaacgtg gacgttcgcg gacatgtcgt 840
cgatgatcac ccgacgcaag tgggagcagg ctggtgctgc agagtattac agggcctacc 900
tggagggcga gtgcgtggag tggctccaca gatacctgaa gaacgggaat gctacgctgc 960
tgcgcacaga ttccccaag gcacatgtga cctatcacc cagatctaaa ggtgaagtca 1020
ccctgagggtg ctgggccctg ggcttctacc ctgctgacat caccctgacc tggcagttga 1080
atggggagga gctgaccag gacatggagc ttgtggagac caggcctgca ggggatggaa 1140
ccttcagaa gtgggcatct gtggtggtgc ctcttgggaa ggagcagaat tacacatgcc 1200
gtgtgtacca tgaggggctg ccccatcccc tcaccctgag atgggagggt ggaataggtt 1260
caggtggcgg tggatcagga ggcgagggtt caatccagaa aaccctcaa attcaagtat 1320
actcacgcca cccaccggag aatgggaagc cgaacatact gaactgctac gtaacacagt 1380
tccaccgcc tcacattgaa atccaaatgc tgaagaacgg gaaaaaatt cctaaagtag 1440
agatgtcaga tatgtccttc agcaaggact ggtctttcta tatctgggt cacactgaat 1500
tcacccccac tgagactgat acatacgct gcagagttaa gcatgacagt atggccgagc 1560
ccaagaccgt ctactgggat cgagacatgg aacaaaagct tatttctgaa gaagacttgt 1620
aatagctcga g                                     1631

```

<210> 30

<211> 540

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 30

```

Met Gln Leu Leu Arg Cys Phe Ser Ile Phe Ser Val Ile Ala Ser Val
  1             5             10             15

```

```

Leu Ala Gln Glu Leu Thr Thr Ile Cys Glu Gln Ile Pro Ser Pro Thr
          20             25             30

```

```

Leu Glu Ser Thr Pro Tyr Ser Leu Ser Thr Thr Thr Ile Leu Ala Asn
          35             40             45

```

```

Gly Lys Ala Met Gln Gly Val Phe Glu Tyr Tyr Lys Ser Val Thr Phe
          50             55             60

```

```

Val Ser Asn Cys Gly Ser His Pro Ser Thr Thr Ser Lys Gly Ser Pro
          65             70             75             80

```

```

Ile Asn Thr Gln Tyr Val Phe Lys Asp Asn Ser Ser Thr Ile Glu Gly
          85             90             95

```

```

Arg Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Gln Ala Ser Gly Gly
          100            105            110

```

```

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Ser Gly
          115            120            125

```

```

Gly Leu Lys Gly Gly Pro Gly Gly Gly Ser Gly Gly Gly Gly Pro His
          130            135            140

```

```

Ser Met Arg Tyr Phe Glu Thr Ala Val Ser Arg Arg Gly Leu Gly Glu
          145            150            155            160

```

Pro Arg Tyr Ile Ser Val Gly Tyr Val Asn Asp Lys Glu Phe Val Arg
 165 170 175
 Phe Asp Ser Asp Ala Glu Asn Pro Arg Tyr Glu Pro Arg Ala Pro Trp
 180 185 190
 Met Glu Gln Glu Gly Pro Glu Tyr Trp Glu Arg Ile Thr Gln Ile Ala
 195 200 205
 Lys Gly Gln Glu Gln Trp Phe Arg Val Asn Leu Arg Thr Leu Leu Gly
 210 215 220
 Tyr Tyr Asn Gln Ser Ala Gly Gly Thr His Thr Leu Gln Trp Met Tyr
 225 230 235 240
 Gly Cys Asp Val Gly Ser Asp Gly Arg Leu Leu Arg Gly Tyr Glu Gln
 245 250 255
 Phe Ala Tyr Asp Gly Cys Asp Tyr Ile Ala Leu Asn Glu Asp Leu Lys
 260 265 270
 Thr Trp Thr Phe Ala Asp Met Ser Ser Met Ile Thr Arg Arg Lys Trp
 275 280 285
 Glu Gln Ala Gly Ala Ala Glu Tyr Tyr Arg Ala Tyr Leu Glu Gly Glu
 290 295 300
 Cys Val Glu Trp Leu His Arg Tyr Leu Lys Asn Gly Asn Ala Thr Leu
 305 310 315 320
 Leu Arg Thr Asp Ser Pro Lys Ala His Val Thr Tyr His Pro Arg Ser
 325 330 335
 Lys Gly Glu Val Thr Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala
 340 345 350
 Asp Ile Thr Leu Thr Trp Gln Leu Asn Gly Glu Glu Leu Thr Gln Asp
 355 360 365
 Met Glu Leu Val Glu Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys
 370 375 380
 Trp Ala Ser Val Val Val Pro Leu Gly Lys Glu Gln Asn Tyr Thr Cys
 385 390 395 400
 Arg Val Tyr His Glu Gly Leu Pro His Pro Leu Thr Leu Arg Trp Glu
 405 410 415
 Gly Gly Ile Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Ile
 420 425 430
 Gln Lys Thr Pro Gln Ile Gln Val Tyr Ser Arg His Pro Pro Glu Asn
 435 440 445
 Gly Lys Pro Asn Ile Leu Asn Cys Tyr Val Thr Gln Phe His Pro Pro
 450 455 460

His Ile Glu Ile Gln Met Leu Lys Asn Gly Lys Lys Ile Pro Lys Val
 465 470 475 480

Glu Met Ser Asp Met Ser Phe Ser Lys Asp Trp Ser Phe Tyr Ile Leu
 485 490 495

Ala His Thr Glu Phe Thr Pro Thr Glu Thr Asp Thr Tyr Ala Cys Arg
 500 505 510

Val Lys His Asp Ser Met Ala Glu Pro Lys Thr Val Tyr Trp Asp Arg
 515 520 525

Asp Met Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
 530 535 540

<210> 31
 <211> 832
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 nucleotide

<400> 31
 gaattctact tcatacattt tcaattaaga tgcagttact tcgctgtttt tcaatatttt 60
 ctgttattgc ttcagtttta gcagctagct tggataaaag agaacaatac aaattctact 120
 cagttcttaa ggggtggacca ggtggagggt caggagggtg aggccacac tcgctgaggt 180
 atttcgtcac cgccgtgtcc cggcccgcc tcggggagcc ccggtacatg gaagtcggct 240
 acgtggacga cacggagttc gtgcgcttcg acagcgacgc ggagaatccg agatatgagc 300
 cgcgggcgcg gtggatggag caggaggggc ccgagtattg ggagcgggag acacagaaag 360
 ccaagggcaa tgagcagagt ttccgagtg acctgaggac cctgctcggc tactacaacc 420
 agagcaaggg cggtctctac actattcagg tgatctctgg ctgtgaagtg gggctccgacg 480
 ggcgactcct ccgcgggtac cagcagtaac cctacgacgg ctgcgattac atcgccctga 540
 acgaagacct gaaaacgtgg acggcggcgg acatggcggc gctgatcacc aaacacaaag 600
 gggagcaggc tggatgaagc gagagactca gggcctacct ggagggcacg tgcgtggaga 660
 ggctccgcag atacctgaag aacgggaacg cgacgctgct gcgcacagat tccccaaag 720
 cccatgtgac ccatcacagc agacctgaag ataaagtcac cctgaggtgc tgggccctgg 780
 gcttctaccc tgctgacatc accctgacct ggcagttgaa tggggaggag ct 832

<210> 32
 <211> 542
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 peptide

<400> 32
 Ile Leu Leu His Thr Phe Ser Ile Lys Met Gln Leu Leu Arg Cys Phe
 1 5 10 15

Ser Ile Phe Ser Val Ile Ala Ser Val Leu Ala Ala Ser Leu Asp Lys
 20 25 30

Arg Glu Gln Tyr Lys Phe Tyr Ser Val Leu Lys Gly Gly Pro Gly Gly
 35 40 45
 Gly Ser Gly Gly Gly Gly Pro His Ser Leu Arg Tyr Phe Val Thr Ala
 50 55 60
 Val Ser Arg Pro Gly Leu Gly Glu Pro Arg Tyr Met Glu Val Gly Tyr
 65 70 75 80
 Val Asp Asp Thr Glu Phe Val Arg Phe Asp Ser Asp Ala Glu Asn Pro
 85 90 95
 Arg Tyr Glu Pro Arg Ala Arg Trp Met Glu Gln Glu Gly Pro Glu Tyr
 100 105 110
 Trp Glu Arg Glu Thr Gln Lys Ala Lys Gly Asn Glu Gln Ser Phe Arg
 115 120 125
 Val Asp Leu Arg Thr Leu Leu Gly Tyr Tyr Asn Gln Ser Lys Gly Gly
 130 135 140
 Ser His Thr Ile Gln Val Ile Ser Gly Cys Glu Val Gly Ser Asp Gly
 145 150 155 160
 Arg Leu Leu Arg Gly Tyr Gln Gln Tyr Ala Tyr Asp Gly Cys Asp Tyr
 165 170 175
 Ile Ala Leu Asn Glu Asp Leu Lys Thr Trp Thr Ala Ala Asp Met Ala
 180 185 190
 Ala Leu Ile Thr Lys His Lys Trp Glu Gln Ala Gly Glu Ala Glu Arg
 195 200 205
 Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Arg Leu Arg Arg Tyr
 210 215 220
 Leu Lys Asn Gly Asn Ala Thr Leu Leu Arg Thr Asp Ser Pro Lys Ala
 225 230 235 240
 His Val Thr His His Ser Arg Pro Glu Asp Lys Val Thr Leu Arg Cys
 245 250 255
 Trp Ala Leu Gly Phe Tyr Pro Ala Asp Ile Thr Leu Thr Trp Gln Leu
 260 265 270
 Asn Gly Glu Glu Leu Ile Gln Asp Met Glu Leu Val Glu Thr Arg Pro
 275 280 285
 Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ser Val Val Val Pro Leu
 290 295 300
 Gly Lys Glu Gln Tyr Tyr Thr Cys His Val Tyr His Gln Gly Leu Pro
 305 310 315 320
 Glu Pro Leu Thr Leu Arg Trp Glu Gly Gly Ile Gly Ser Gly Gly Gly
 325 330 335

Gly Ser Gly Gly Gly Gly Ser Ile Gln Lys Thr Pro Gln Ile Gln Val
 340 345 350
 Tyr Ser Arg His Pro Pro Glu Asn Gly Lys Pro Asn Ile Leu Asn Cys
 355 360 365
 Tyr Val Thr Gln Phe His Pro Pro His Ile Glu Ile Gln Met Leu Lys
 370 375 380
 Asn Gly Lys Lys Ile Pro Lys Val Glu Met Ser Asp Met Ser Phe Ser
 385 390 395 400
 Lys Asp Trp Ser Phe Asn Ile Leu Ala His Thr Glu Phe Thr Pro Thr
 405 410 415
 Glu Thr Asp Thr Tyr Ala Cys Arg Val Lys His Asp Ser Met Ala Glu
 420 425 430
 Pro Lys Thr Val Tyr Trp Asp Arg Asp Met Glu Gln Arg Leu Ile Ser
 435 440 445
 Glu Glu Asp Leu His Met Gln Glu Leu Thr Thr Ile Cys Glu Gln Ile
 450 455 460
 Pro Ser Pro Thr Leu Glu Ser Thr Pro Tyr Ser Leu Ser Thr Thr Thr
 465 470 475 480
 Ile Leu Ala Asn Gly Lys Ala Met Gln Gly Val Phe Glu Tyr Tyr Lys
 485 490 495
 Ser Val Thr Phe Val Ser Asn Cys Gly Ser His Pro Ser Thr Thr Ser
 500 505 510
 Lys Gly Ser Pro Ile Asn Thr Gln Tyr Val Phe Lys Asp Asn Ser Ser
 515 520 525
 Thr Ile Glu Gly Arg Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 530 535 540

<210> 33

<211> 720

<212> DNA

<213> Artificial Sequence

<220>

 <223> Description of Artificial Sequence: Synthetic
 nucleotide

<400> 33

gaattctact tcatacat ttc aattaaga tgcagttact tcgctgtttt tcaatat tttt 60
 ctgttattgc ttcagtttta gcagctagct tggataaaaag agaacaatac aaattctact 120
 cagttcttaa ggggtggacca ggtggagggt caggaggtgg aggccacac tcgctgaggt 180
 atttcgtcac cgccgtgtcc cgcccgcc tggggagcc ccggtacatg gaagtcggct 240
 acgtggacga cacggagttc gtgcgcttcg acagcgacgc ggagaatccg agatatgagc 300
 cgcgggcgcg gtggatggag caggaggggc ccgagtattg ggagcgggag acacagaaag 360
 ccaagggcaa tgagcagagt ttccgagtggt acctgaggac cctgctcggc tactacaacc 420

agagcaaggg cggctctcac actattcagg tgatctctgg ctgtgaagtg ggggccgacg 480
 ggcgactcct cgcgggttac cagcagtacg cctacgacgg ctgcgattac atcgccctga 540
 acgaagacct gaaaacgtgg acggcggcgg acatggcggc gctgatcacc aaacacaagt 600
 gggagcaggc tgggtgaagca gagagactca gggcctacct ggagggcacg tgcgtggagc 660
 ggctccgcag atacctgaag aacgggaacg cgacgctgct gcgcacagat tcdccaaagg 720

<210> 34

<211> 542

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 34

Ile Leu Leu His Thr Phe Ser Ile Lys Met Gln Leu Leu Arg Cys Phe
 1 5 10 15

Ser Ile Phe Ser Val Ile Ala Ser Val Leu Ala Ala Ser Leu Asp Lys
 20 25 30

Arg Glu Gln Tyr Lys Phe Tyr Ser Val Leu Lys Gly Gly Pro Gly Gly
 35 40 45

Gly Ser Gly Gly Gly Gly Pro His Ser Leu Arg Tyr Phe Val Thr Ala
 50 55 60

Val Ser Arg Pro Gly Leu Gly Glu Pro Arg Tyr Met Glu Val Gly Tyr
 65 70 75 80

Val Asp Asp Thr Glu Phe Val Arg Phe Asp Ser Asp Ala Glu Asn Pro
 85 90 95

Arg Tyr Glu Pro Arg Ala Arg Trp Met Glu Gln Glu Gly Pro Glu Tyr
 100 105 110

Trp Glu Arg Glu Thr Gln Lys Ala Lys Gly Asn Glu Gln Ser Phe Arg
 115 120 125

Val Asp Leu Arg Thr Leu Leu Gly Tyr Tyr Asn Gln Ser Lys Gly Gly
 130 135 140

Ser His Thr Ile Gln Val Ile Ser Gly Cys Glu Val Gly Ser Asp Gly
 145 150 155 160

Arg Leu Leu Arg Gly Tyr Gln Gln Tyr Ala Tyr Asp Gly Cys Asp Tyr
 165 170 175

Ile Ala Leu Asn Glu Asp Leu Lys Thr Trp Thr Ala Ala Asp Met Ala
 180 185 190

Ala Leu Ile Thr Lys His Lys Trp Glu Gln Ala Gly Glu Ala Glu Arg
 195 200 205

Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Arg Leu Arg Arg Tyr
 210 215 220

Leu Lys Asn Gly Asn Ala Thr Leu Leu Arg Thr Asp Ser Pro Lys Ala
 225 230 235 240
 His Val Thr His His Ser Arg Pro Glu Asp Lys Val Thr Leu Arg Cys
 245 250 255
 Trp Ala Leu Gly Phe Tyr Pro Ala Asp Ile Thr Leu Thr Trp Gln Leu
 260 265 270
 Asn Gly Glu Glu Leu Ile Gln Asp Met Glu Leu Val Glu Thr Arg Pro
 275 280 285
 Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ser Val Val Val Pro Leu
 290 295 300
 Gly Lys Glu Gln Tyr Tyr Thr Cys His Val Tyr His Gln Gly Leu Pro
 305 310 315 320
 Glu Pro Leu Thr Leu Arg Trp Glu Gly Gly Ile Gly Ser Gly Gly Gly
 325 330 335
 Gly Ser Gly Gly Gly Gly Ser Ile Gln Lys Thr Pro Gln Ile Gln Val
 340 345 350
 Tyr Ser Arg His Pro Pro Glu Asn Gly Lys Pro Asn Ile Leu Asn Cys
 355 360 365
 Tyr Val Thr Gln Phe His Pro Pro His Ile Glu Ile Gln Met Leu Lys
 370 375 380
 Asn Gly Lys Lys Ile Pro Lys Val Glu Met Ser Asp Met Ser Phe Ser
 385 390 395 400
 Lys Asp Trp Ser Phe Tyr Ile Leu Ala His Thr Glu Phe Thr Pro Thr
 405 410 415
 Glu Thr Asp Thr Tyr Ala Cys Arg Val Lys His Asp Ser Met Ala Glu
 420 425 430
 Pro Lys Thr Val Tyr Trp Asp Arg Asp Met Glu Gln Lys Leu Ile Ser
 435 440 445
 Glu Glu Asp Leu His Met Gln Glu Leu Thr Thr Ile Cys Glu Gln Ile
 450 455 460
 Pro Ser Pro Thr Leu Glu Ser Thr Pro Tyr Ser Leu Ser Thr Thr Thr
 465 470 475 480
 Ile Leu Ala Asn Gly Lys Ala Met Gln Gly Val Phe Glu Tyr Tyr Lys
 485 490 495
 Ser Val Thr Phe Val Ser Asn Cys Gly Ser His Pro Ser Thr Thr Ser
 500 505 510
 Lys Gly Ser Pro Ile Asn Thr Gln Tyr Val Phe Lys Asp Asn Ser Ser
 515 520 525

Thr Ile Glu Gly Arg Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
 530 535 540

<210> 35
 <211> 1091
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 nucleotide

<400> 35
 gaattctact tcatatattt tcaattaaga tgcagttact tcgctgtttt tcaatatttt 60
 ctgttattgc ttcatgttta gcagctagct tggataaaaag agaacaatac aaattctact 120
 cagttcttaa ggggtggacca ggtggagggt caggagggtg agggccacac tcgctgaggt 180
 atttcgtcac cgccgtgtcc cgcccgggcc tcggggagcc cgggtacatg gaagtgggct 240
 acgtggacga caccgagttc gtgcgcttca acagcgacgc ggagaatccg agatatgagc 300
 cgcgggcgcg gtggatggag caggaggggc ccgagtattg ggagcgggag acacagaaaag 360
 ccaagggcaa tgagcagagt ttccgagtgg acctgaggac cctgctcggc tactacaacc 420
 agagcaaggg cggtctcac actattcagg tgatctctgg ctgtgaagtg ggggtccgacg 480
 ggcgactcct ccgcggttac cagcagtacg cctacgacgg ctgctgattac atcgccctga 540
 acgaagacct gaaaacgtgg acggcgggcg acatggcggc gctgatcacc aaacacaagt 600
 gggagcaggc tgggtgaagca gagagactca gggcctacct ggagggcacg tgcgtggaga 660
 ggctccgcag atacctgaag aacgggaacg cgacgctgct gcgcacagat tccccaaagg 720
 cccatgtgac ccatcacagc agacctgaag ataaagtcac cctgagggtgc tggggccctgg 780
 gcttctaccc tgctgacatc accctgacct ggcagttgaa tggggaggag ctgatccagg 840
 acatggagct tgtggagacc aggcctgcag gggatggaac cttccagaag tgggcatctg 900
 tgggtggtgcc tcttgggaag gagcagtatt acacatgcca tgtgtaccat caggggctgc 960
 ctgagcccct caccctgaga tgggaggggtg gaatagggtc aggtggcggt ggatcaggag 1020
 gcggagggtc aatccagaaa acccctcaaa ttcaagtata ctcacgccac ccaccggaga 1080
 atgggaagcc g 1091

<210> 36
 <211> 542
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 peptide

<400> 36
 Ile Leu Leu His Thr Phe Ser Ile Lys Met Gln Leu Leu Arg Cys Phe
 1 5 10 15
 Ser Ile Phe Ser Val Ile Ala Ser Val Leu Ala Ala Ser Leu Asp Lys
 20 25 30
 Arg Glu Gln Tyr Lys Phe Tyr Ser Val Leu Lys Gly Gly Pro Gly Gly
 35 40 45
 Gly Ser Gly Gly Gly Gly Pro His Ser Leu Arg Tyr Phe Val Thr Ala
 50 55 60
 Val Ser Arg Pro Gly Leu Gly Glu Pro Arg Tyr Met Glu Val Gly Tyr
 65 70 75 80

Val Asp Asp Thr Glu Phe Val Arg Phe Asn Ser Asp Ala Glu Asn Pro
 85 90 95
 Arg Tyr Glu Pro Arg Ala Arg Trp Met Glu Gln Glu Gly Pro Glu Tyr
 100 105 110
 Trp Glu Arg Glu Thr Gln Lys Ala Lys Gly Asn Glu Gln Ser Phe Arg
 115 120 125
 Val Asp Leu Arg Thr Leu Leu Gly Tyr Tyr Asn Gln Ser Lys Gly Gly
 130 135 140
 Ser His Thr Ile Gln Val Ile Ser Gly Cys Glu Val Gly Ser Asp Gly
 145 150 155 160
 Arg Leu Leu Arg Gly Tyr Gln Gln Tyr Ala Tyr Asp Gly Cys Asp Tyr
 165 170 175
 Ile Ala Leu Asn Glu Asp Leu Lys Thr Trp Thr Ala Ala Asp Met Ala
 180 185 190
 Ala Leu Ile Thr Lys His Lys Trp Glu Gln Ala Gly Glu Ala Glu Arg
 195 200 205
 Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Arg Leu Arg Arg Tyr
 210 215 220
 Leu Lys Asn Gly Asn Ala Thr Leu Leu Arg Thr Asp Ser Pro Lys Ala
 225 230 235 240
 His Val Thr His His Ser Arg Pro Glu Asp Lys Val Thr Leu Arg Cys
 245 250 255
 Trp Ala Leu Gly Phe Tyr Pro Ala Asp Ile Thr Leu Thr Trp Gln Leu
 260 265 270
 Asn Gly Glu Glu Leu Ile Gln Asp Met Glu Leu Val Glu Thr Arg Pro
 275 280 285
 Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ser Val Val Val Pro Leu
 290 295 300
 Gly Lys Glu Gln Tyr Tyr Thr Cys His Val Tyr His Gln Gly Leu Pro
 305 310 315 320
 Glu Pro Leu Thr Leu Arg Trp Glu Gly Gly Ile Gly Ser Gly Gly Gly
 325 330 335
 Gly Ser Gly Gly Gly Gly Ser Ile Gln Lys Thr Pro Gln Ile Gln Val
 340 345 350
 Tyr Ser Arg His Pro Pro Glu Asn Gly Lys Pro Asn Ile Leu Asn Cys
 355 360 365
 Tyr Val Thr Gln Phe His Pro Pro His Ile Glu Ile Gln Met Leu Lys
 370 375 380

```

Asn Gly Lys Lys Ile Pro Lys Val Glu Met Ser Asp Met Ser Phe Ser
385                      390                      395                      400

Lys Asp Trp Ser Phe Asn Ile Leu Ala His Thr Glu Phe Thr Pro Thr
                      405                      410                      415

Glu Thr Asp Thr Tyr Ala Cys Arg Val Lys His Asp Ser Met Ala Glu
                      420                      425                      430

Pro Lys Thr Val Tyr Trp Asp Arg Asp Met Glu Gln Arg Leu Ile Ser
                      435                      440                      445

Glu Glu Asp Leu His Met Gln Glu Leu Thr Thr Ile Cys Glu Gln Ile
450                      455                      460

Pro Ser Pro Thr Leu Glu Ser Thr Pro Tyr Ser Leu Ser Thr Thr Thr
465                      470                      475                      480

Ile Leu Ala Asn Gly Lys Ala Met Gln Gly Val Phe Glu Tyr Tyr Lys
                      485                      490                      495

Ser Val Thr Phe Val Ser Asn Cys Gly Ser His Pro Ser Thr Thr Ser
                      500                      505                      510

Lys Gly Ser Pro Ile Asn Thr Gln Tyr Val Phe Lys Asp Asn Ser Ser
515                      520                      525

Thr Ile Glu Gly Arg Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
530                      535                      540

```

<210> 37

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 37

His Tyr Ser Pro Phe Arg Gln Leu Ala

1

5